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MEETING ABSTRACTS
A1
Moving lupus epidemiology forward: returning to the basics
Julia F Simard
Stanford School of Medicine, Stanford, CA, USA
E-mail: jsimard@stanford.edu
Arthritis Research & Therapy 2014, 16(Suppl 1):A1
The protracted diagnostic period and variable disease presentation not only
complicate diagnosing SLE but also the epidemiologic study of it. Coupled
with the remitting and relapsing nature of the disease and the challenges in
managing it, clinical research in lupus requires careful attention to study
design, control selection, temporality, and many often overlooked issues in
the analysis phase. Between “big data” and the impressive advances in the
basic sciences, it is tempting to either oversimplify methods to take
advantage of “big data” or overcomplicate because the problem itself is
complicated.
As we revisit the building blocks of epidemiologic research, we will
uncover opportunities to move epidemiology and clinical research forward
in SLE. Why do we care about effect modification and what is it? Why can
we not just adjust for everything that we want to? And perhaps, most
importantly, going back to the very beginning and asking ourselves: does
this matter?
During this talk we will discuss issues relating to case identification methods,
potential biases associated with control selection, and return to the basics of
epidemiologic research. Although we shall discuss these issues in the
context of environmental (nongenetic) factors, these concerns extend across
the worlds of observational data analysis, can impact randomized trials, and
are relevant for all types of exposures and outcomes.
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Is prevention of systemic lupus erythematosus a goal?
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Background: Prevention of systemic lupus erythematosus (SLE) presents
many challenges. By contrast, prevention of acquired immunodeficiency
syndrome (AIDS) is relatively straightforward: an infective agent has been
identified, risk behaviors are well-delineated, antiviral therapeutics are
highly effective and neonates have been apparently cured. Lupus is a
more complex disease, with a significant but incompletely defined genetic
component, widely heterogeneous manifestations and major gaps in
knowledge about pathogenesis.
Methods: The characteristic features of SLE can be exploited in the quest
for preventive strategies. One of these is the presence of a latent phase
during which expressed autoantibodies are increasing in number and
complexity prior to the onset of clinical symptoms. This offers a path to the
development of screening blood tests that would be cost-effective and
generally acceptable to subjects. ANA alone is clearly not sufficient
to establish risk, as it is highly prevalent in the healthy population.
Alternatively, a panel of autoantibodies, possibly combined with cytokines
and gene expression levels, might be useful. The skewed demographics of
SLE can also be exploited, including the higher prevalence in females, first-
degree relatives and individuals < 40 years old, permitting focus on those
who are most likely to be at risk.
Results: A composite index, with demographics and multiplex blood
autoantibody profiles, has been proposed. This index showed statistically
significant correlation with progression of disease in a small prospective
cohort (P =1×1 0
−7). As the science improves, the risk definition could be
augmented with targeted genetic information, as is now available for
several inherited cancers; even the simple inclusion of family history as a
proxy for genetic input might be of value. All such screening efforts would
be for naught in the absence of an available intervention. Fortunately,
several candidate treatments are available for the incomplete lupus
phenotypes, and precedent for using therapeutics in individuals who are not
yet ill has been established in other conditions, notably type I diabetes
mellitus.
Conclusions: It is timely to propose a prevention trial in individuals at high
risk for development of SLE. A placebo arm would probably be required in
such a study to show that the enrollment criteria successfully identified
high-risk individuals. Challenges to trial design include acceptance of “no
treatment” by persons profiled as high risk and the relatively long timeline
likely to be required to achieve observable clinical change. However, despite
these issues, available tools and therapeutics make prevention trials in SLE a
feasible, near-term prospect.
A3
Are patient ratings of interactions with providers and health plans
associated with technical quality of care in systemic lupus
erythematosus?
Edward Yelin
*, Laura Trupin, Jinoos Yazdany
University of California, San Francisco, San Francisco, CA, USA
E-mail: ed.yelin@ucsf.edu
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Background: Prior research has shown that the technical quality of SLE care
is associated with the degree of subsequent accumulated damage. However,
it is not known whether the nature of interactions between patients and
providers and health systems is associated with the technical quality of care.
Methods: We analyzed data from the UCSF Lupus Outcomes Study (LOS),
a national sample of persons with SLE interviewed annually using a
structured telephone survey. The survey includes batteries from the
Consumer Assessment of Health Plans developed by the US Agency for
Healthcare Research and Quality and the Interpersonal Processes of Care
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communication, shared decision-making, and trust) and health systems
(promptness/timeliness of care, care coordination, and assessment of
health plans) from 0 to 100. Due to the fact that the ratings were not
normally distributed, we dichotomized the measures at the lowest versus
the highest three quartiles. The survey also includes the 13 quality
indicators (QIs) for SLE that can be reliably reported by patients. The QIs
were aggregated into a pass rate, defined as the number of QIs received
as a proportion of those for which individuals are eligible. We used
generalized estimating equations to model the relationship of the QI pass
rate with being in the lowest quartile of ratings of each individual
dimension and with being in the lowest quartile on zero, one to three,
and four to six of the dimensions. Models were adjusted for age, race/
ethnicity, education, poverty status, presence and kind of health
insurance, specialty of principal SLE physician, disease duration, disease
activity (SLAQ), and disease damage (BILD).
Results: A total of 640 LOS participants with ≥1 visit to their principal SLE
provider in the year prior to interview were eligible for analysis. Mean age
was 52.8 ± 12.6 years and mean disease duration was 20.1 ± 8.8 years;
38% were nonwhites, and 14% were in poverty. Being in the lowest
quartile of ratings on any one individual dimension was not associated
with a statistically significant difference in QI pass rates (data not shown).
Being in the lowest quartile of ratings on four to six dimensions was
associated with significantly lower pass rates (0.63 vs. 0.71 for those in
the lowest quartile on no dimensions, P = 0.02) (Table 1).
Conclusions: Low ratings on multiple dimensions of interactions may be
a sentinel for poor technical quality of care. In the USA, ratings of
providers and health plans are in the public domain and this information
can help persons with SLE choose providers and health plans more likely
to achieve high technical quality of care.
Acknowledgements: NIAMS Grants P60 AR05308 and R01 AR056476 and
Robert Wood Johnson Investigator Award in Health Policy Research.
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Background: In SLE, pathogenic mechanisms responsible for immune
activation, immune deposit formation, cell infiltration and organ damage
are complex and variable. However, immune cells and their products
contribute to the nature and intensity of organ involvement as well as the
host’s response to therapy. In many respects, renal involvement is a
microcosm of systemic disease, with variable glomerulonephritis,
interstitial nephritis and vasculitis. Both systemic autoimmune and renal
cellular responses influence individual disease phenotype. Nevertheless,
antigenic specificity determines local events, in particular where immune
deposits form. Direct binding of autoantibodies to glomerular antigens is
particularly relevant, and the site of complex formation, along with the
capacity of deposited Ig to engage FcR and activate complement play
important roles in disease expression. Cellular infiltration (for example,
T cells, B cells, macrophages) and the renal cellular response to these
events are also important and influential. For the most part, therapy is
systemic and directed at controlling inflammation and autoimmunity,
rationalizing that limiting autoreactivity and inflammatory cell infiltration
will control disease. Although this approach is somewhat efficacious, it has
limitations. Thus, we reasoned that in some circumstances, targeted
therapy could provide advantage of better ongoing disease in a given
organ, while sparing systemic side effects.
Methods: To approach this problem, we postulated that human
monoclonal anti-a3(IV) antibodies (Ab) that localize in glomeruli could serve
as vehicles for targeted drug delivery for glomerular diseases, including
lupus nephritis. As a potential disease-modifying agent, we took advantage
of recent observations that PGE2 enhanced renal cellular recovery and
regeneration after established immunologic injury during the course of
nephrotoxic nephritis (NTN). To enhance efficacy and limit undesirable
systemic effects and target the kidney, PGE2 was coupled to a human
monoclonal anti-a3(IV) Ab. Given enhanced glomerular expression of a3(IV),
with very limited epitope exposure in other organs, it provides an ideal
target for delivery of glomerular disease modifying agents. Therefore, PGE2
was chemically linked to human anti-a3(IV) Ab. Chemical composition of
conjugates was assessed by western blotting, and preserved anti-a3(IV)
activity was confirmed by ELISA.
Results: Initially, glomerular localization of the anti-a3(IV) Ab-PGE2
conjugates was determined after injection in normal mice (IF). Once
confirmed, the capacity of the conjugates to modify disease was determined
during established NTN. Proteinuria, BUN levels and histology normalized in
PGE2 conjugate-treated mice, as compared with untreated mice or mice
treated with an equivalent dose of PGE2 alone.
Conclusions: The results provide a novel means of targeting glomeruli
during systemic disease, by providing efficient drug delivery, while limiting
systemic effects.
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Skin findings in lupus erythematosus: The skin findings in lupus
erythematosus include lupus-specific and lupus-nonspecific categorizations.
Lupus specific includes chronic cutaneous, subacute cutaneous, and acute
cutaneous lupus. Lupus-specific findings include having a skin biopsy that
shows LE-specific histology. The diagnosis of cutaneous lupus can be made
regardless of whether the patient meets ACR or SLICC criteria for lupus.
Lupus-nonspecific skin findings refer to lesions such as vasculitis or
urticaria, where the findings are not histopathologically distinct for lupus
and/or may be seen as a feature of other disease processes beyond lupus
erythematosus. Chronic cutaneous lupus includes localized, generalized,
and hypertrophic lupus, lupus panniculitis, and papulomucinous lupus.
There is currently an ongoing international Delphi approach to unify the
classification of cutaneous lupus, since the ongoing proliferation of how
best to group the various presentations of cutaneous lupus is confusing.
Skin and SLE criteria: Four of the SLE criteria are dermatologic, and the
number of skin criteria contributes to there being many skin predominant
lupus patients who meet criteria for SLE. Another approach to how best to
classify SLE was recently published by the SLICC group. There is recognition
of the variety of skin lesions that can be seen with the new criteria, but
some criteria such as alopecia may be difficult in terms of attribution to
lupus. The specificity of the new criteria will require ongoing investigation.
In addition, some patients with cutaneous lupus initially do progress to SLE,
but recent data suggest that, during progression to SLE, the SLE criteria are
often met with skin, arthritis, hematologic, and serologic findings.
Pathophysiology and triggers of cutaneous lupus erythematosus:
The pathophysiologic findings of cutaneous lupus include interface
dermatitis, with dendritic cells, CD4 and CD8 lymphocytes, and activation of
innate immune proteins, including antimicrobial peptides. An interferon
signature is seen in the skin and frequently in the blood with patients with
cutaneous lupus, and this correlates with the activity of lupus in the skin.
There is evidence that medications are a frequent trigger of subacute
cutaneous lupus, with about one-third of patients having drugs as a trigger
or aggravating factor. In particular, medications such as terbinafine, TNF
inhibitors, and omeprazole, in addition to usual culprits such as thiazide,
should be considered as risk factors.
Quality of life and cutaneous lupus erythematosus: Recent studies
indicate an extremely large impact of cutaneous lupus on quality of life,
Table 1(abstract A3) Technical quality of care pass rates
by ratings of healthcare experiences in SLE, aggregate
Number of dimensions QI pass rate (95% CI)
None 0.71 (0.68, 0.74)
One to three 0.70 (0.67, 0.72)
Four to six 0.63 (0.58, 0.68)
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demonstrate that domains related to mental health, role emotion, and
social function are worse in cutaneous lupus than in type II diabetes and
recent myocardia infarction. Sixty percent of cutaneous lupus patients are
depressed.
Measurement of disease severity in cutaneous lupus erythematosus:
The cutaneous lupus erythematosus area and severity index (CLASI) is a way
to measure skin severity. The CLASI has undergone many validation studies
for inter-rater and intra-rater reliability, responsiveness, correlation with QoL,
and correlation with disease biomarkers. The CLASI has been studied in
many different ethnic and racial groups, and has now been used in large
international multicenter trials. These studies have demonstrated the
importance of smoking as a risk factor for onset and severity in cutaneous
lupus, as well as lack of responsiveness to current treatments.
Treatment of cutaneous lupus erythematosus: There is still a paucity of
successful trials for cutaneous lupus. Hydroxychloroquine works for 50 to
60% of patients. Addition of quinacrine to hydroxychloroquine can improve
response in two-thirds of patients refractory to hydroxychloroquine alone.
There is a correlation of hydroxychloroquine levels with response.
Lenalidomide appears to have been beneficial in two small open-label trials
of refractory cutaneous lupus. Rituximab has helped some patients with
refractory bullous lupus, a disease normally mediated by antibodies against
type VII collagen. With the improved understanding of pathogenesis,
measures of disease severity, and the understanding of the impact of lupus
skin disease on patients, there is increasing interest in improving the
approaches to treatment for patients.
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Background: Looking forward to preclinical risk assessment and
early interventions: A major aspiration of clinical medicine is early
diagnosis and interventions that interrupt autoimmune diseases in its
earliest stages, before they become increasingly difficult and dangerous to
treat. Definition of the relative contributions of three critical components at
the earliest phases of disease is required to realize this goal: 1) genes; 2)
environment; and 3) chance. Lupus, like all common human disorders,
results from the interplay of these components. Currently >35 allelically
variant genes, many of which are shared with other autoimmune disorders,
are reported to contribute to the pathogenesis of lupus. The roadmap for
genetic risk assessment is relatively straightforward. Even given that present
studies are confounded by the failure of defined genetic variation to fully
account for disease heritability, definition of the genetic components can be
generated digitally through deep genome sequencing, genome wide
association (GWA) studies and family linkage studies. However, thinking
forward to the best-case scenario in which all heritability is explained, there
will still be a substantial gap. This gap is commonly attributed to unknowns
casually referred to as environmental factors and chance events. The
importance of these extragenetic unknowns is underscored by studies of
monozygotic twins, which have typically revealed >70% discordance for
common autoimmune syndromes, including lupus. While epigenetic
mechanisms may eventually explain some of this discordance, nebulously
defined environmental factors and chance will continue to cloud genome-
based risk prognostications and limit the potential for identifying individuals
with sufficient genetic evidence to justify early interventions.
What are contributions of environment?: The identification of relevant
environmental factors is in its infancy. Lupus flares caused by sunburn and
drug-induced lupus-like syndromes stand out as well described environmental
triggers, but the larger question of environmental exposure history, including
prior viral infections, gut microbiome composition, chemical exposures, and
what have you, that promote lupus pathogenesis will only be incrementally
solved. Extracting the contributions of environmental factors would be made
more tractable by first understanding the extent to which chance confounds
the ability to derive cause-effect relationships between environment and
disease.
What is the contribution of chance?: That which cannot be attributed to
environmental factors would logically fall into the nebulous category of
chance, termed more scientifically as stochastic behavior. This indeterminate
parameter is increasingly recognized to be an integral component of all
physical and biological systems. The prototype is Brownian motion of a
particle traveling through a solution and colliding with molecules in a
random manner. While random and unpredictable at the inception,
stochastic behavior become biologically relevant if the “collision” initiates a
chain of molecular and/or cellular processes that evolve into measurable
“deterministic” behaviors. Thus, the chance engagement of molecule A with
molecule B within a critical cell type cell or the chance cognate engagement
of a critical cell type (such as a naïve CD4
+ T cell) with an antigen presenting
cell (APC) could trigger the development of lupus.
The intrinsic variability of inbred strains of laboratory mice provides
a means to understand the impact of stochastic behavior on disease:
Investigation into the potential contributions of stochastic factors in
complex disease processes is not practical in humans. Inbred strains of
laboratory mice are the mammalian organism best suited for the task.
Missing heritability as a confounding factor is negligible in highly inbred
laboratory mice of the same inbred strain because each mouse is an
identical twin. Environmental variation that cannot be readily controlled in
humans can be minimized in mice by consistent husbandry in a stable
laboratory colony.
The BXSB.Yaa model of lupus: BXSB male mice carrying the Yaa mutation
spontaneously develop a systemic autoimmune disease with multiple
similarities to severe forms of human lupus. A duplicated copy of Toll-like
receptor 7 (Tlr7) caused by the Yaa mutation is the primary genetic cause of
this lethal lupus-like disease. The consequence of the Tlr7 duplication -
realized only in Yaa males - is the potent evocation of the IFN1 response
starting at a remarkably young age and the development of follicular T cells
(TFH) that secrete IL21 and drive massive germinal center B cell and
plasmablast expansions. This results in high levels of autoantibodies to RNA,
DNA and other self-antigens, formation of nucleic acid containing immune
complexes and lethal immune complex-mediated glomerulonephritis that
lead to premature deaths.
Methods and results: Robust variation in the autoimmune disease
outcomes is apparent in individual BXSB.Yaa with uniform genetics
and husbandry environment: BXSB.Yaa mice have been inbred for at
least 100 generations, 50 of which were performed in our colony. At least to
the depth of genetic analysis performed to date, our BXSB.Yaa colony is
genetically fixed. Moreover, continuous microbial monitoring has not
revealed any changes over the last 20 years. Thus as a first approximation
the environment in our BXSB.Yaa research colony is notably stable.
However, we repeatedly observe substantial variation in the timing and
severity of autoimmune disease among individual, highly inbred BXSB.Yaa
mice in well-powered studies measuring overall mouse survival (example
Figure 1A). This variation is not consistent with genetic drift and/or fitness
selection for healthier breeders. Substantial disease variation determined
here by outcomes (timing of survival) is a durable feature of inbred BXSB.
Yaa mice.
Robust variation in longitudinal expression of TFH in blood is observed
in BXSB.Yaa mice at early stages of disease: Variation in the survival times
of BXSB.Yaa would predict that biomarkers of mechanistically important
cellular processes would vary similarly. Variation in such biomarkers at early
stages of disease would be of most value because they may identify targets
for early therapeutic interventions. TFH are critical drivers of the BXSB.Yaa
disease. Preliminary longitudinal studies investigating the expression of
circulating ICOS
+ CD4
+ T cells show remarkable individual variation in the
frequencies of these cells by at least 8 weeks of age (Figure 1B). While such
results are not yet linked to the timing of survival of the mice or correlated
with other important biomarkers of disease, it is reasonable to surmise that
stochastic events acting within weeks of birth bifurcate into important
deterministic processes (activation and expansions of TFH in this case) that
m a yb eh a v el o n gt e r mc o n s e q u e n c e s .
Conclusions: Much can be learned by embracing the concept of
stochastic behavior: The principles described here are unlikely to be
restricted to BXSB.Yaa mice. Virtually all genetically homogenous models of
disease demonstrate a range of variation in disease timing and severity. It is
therefore likely that stochastic principles broadly underlie the individual
variations commonly observed in inbred mouse models of disease.
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studies are usually designed to override “stochastic noise” by attempts to
size comparator cohorts with sufficient discriminative power to override
individual variability. When significance in cohort comparisons is not
achieved, the null hypothesis is invoked. The individual variability within
genetically matched cohorts is an untapped source of biological information
that can inform causal mechanisms of disease.
Extrapolation to disease prognosis and early interventions in
humans: Variation in the severity and presentation among individuals
diagnosed with a human autoimmune disease is the rule rather than the
exception. While genetic risk and environment factors are certain to play
important parts, the considerable phenotypic variation described above
underscores the potential for stochastic behaviors to contribute significantly to
disease variation. Genetically and environmentally fixed BXSB.Yaa mice exhibit
patterns that are consistent with stochastic events giving rise to key
deterministic events at the inception of autoimmune disease. By extrapolation,
therapeutic interventions designed to abrupt such early fate decisions may
head off lupus at its inception and have enduring effects on overall disease
pathogenesis (Figure 1B).
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Background: The myriad of mouse genetic alterations that result in a
lupus-like phenotype and the >100 genes now known to be involved in
human lupus are all probably only a hint at the potential complexity of the
many mechanisms that lead to systemic lupus erythematosus (SLE).
Methods: We have applied exome sequencing to 24 SLE patients and their
parents (trios) in an effort to conquer the data analysis and to identify
candidate genes that may contribute when the activity of their gene
products were substantially altered.
Results: The proband of one of our SLE trios had de novo mutations in
RAD54B that was predicted to change ARG to GLN and to be severely
damaging to protein product activity by multiple algorithms. A second much
more conservative de novo mutation in DOCK8 was not predicted to be
consequential. RAD54B is a component of the homologous recombination
DNA repair pathway. Cells from the SLE proband were unusually sensitive to
ionizing radiation by the colony survival and comet tail assays. Ionizing
radiation selectively induced interferon responsive genes in cells from this
patient and not from controls. Transfection of the wild-type gene into the
cells from this patient led to overexpression of the RAD54B gene product and
returned ionizing radiation resistance toward normal.
Conclusion: These data in addition to the other five other genes directly
or indirectly involved in altering risk of SLE by influencing DNA repair
(TREX1, RAD51B, XRCC1, XRCC3,a n dXRCC4) implicate base excision repair,
nonhomologous end joining, and homologous recombination. These
results suggest that multiple DNA repair mechanisms contribute to SLE
susceptibility.
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Background: Systemic lupus erythematosus (SLE) is an autoimmune
disorder characterized by the progressive loss of tolerance to nuclear
antigens and the production of pathogenic autoantibodies. Genetic
polymorphisms in genes involved in B-cell signaling, PTPN22, CSK, BLK and
BANK1, are associated with susceptibility to SLE.
Methods: We have utilized a cohort of genotyped healthy subjects to
better understand how these genetic variants contribute to the failure of
B-cell tolerance seen in SLE. PBMC from these subjects are analyzed using
multiparameter flow cytometry to assess the composition of the B-cell
compartment and the response of B cells to stimulation via BCR and CD40.
Results: Our studies in healthy subjects who carry this variant have
demonstrated alterations in the composition of the transitional and naïve
B-cell pool. This is functionally correlated with the altered BCR response and
enhanced survival of these cells in carriers of the risk variant. Three
potentially functional BANK1 SNPs (including a splice branch point-site
variant and two coding variants) are associated with SLE. We have shown
that the BANK1 risk variants are associated with homeostatic changes in the
peripheral B-cell pool that include a significant expansion of the total
memory and preswitch memory compartment; and a significant decrease in
Figure 1(abstract A6) A, Considerable individual variation in the survival of BXSB. Yaa male mice, n = 93. Long term survival of 26 males carrying
the C57BL/6 Y chromosome (B6Y) demonstrate the dependency of the autoimmune disease on Yaa. B, Longitudinal phenotyping of a cohort of BXSB.
Yaa mice for ICOS
+ CD4
+ T cells. Each line represents data from FACS analysis of blood white blood cells from individual mice. Transition from stochastic
to deterministic occurs at 6-8 weeks of age. Therapies applied at this point are predicted to have the potential of preventing this transition.
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studies we have demonstrated that the BANK1 splice variant is associated
with significantly reduced expression of the Δ2 isoform and that the risk
haplotype is further associated with blunted proximal BCR signaling in naïve
B cells and enhanced p-AKT in memory B cells. Studies are ongoing to
investigate the impact of the BANK1 variant on plasma cell differentiation.
Conclusions: Studies of healthy subjects who carry SLE risk genes
demonstrate alterations in B-cell function and fate. These studies can then
be extended to subjects with SLE to understand how these genetic variants
impact B-cell development and tolerance in the setting of disease.
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Background: DNA methylation, an epigenetic modification, influences gene
expression and has been implicated in the pathogenesis of systemic lupus
erythematosus (SLE). Two recent studies suggest that interferon-regulated
genes are hypomethylated in SLE patients compared with unaffected
controls. However, these studies have not examined whether DNA
methylation is associated with specific disease manifestations. The goal for
the current study was to determine whether differential DNA methylation is
associated with autoantibody production in SLE, with a focus on the anti-
dsDNA autoantibody.
Methods: The methylation status of 467,314 CpG sites across the genome
was characterized for 326 women with SLE. Associations between anti-
dsDNA autoantibody production and methylation status was assessed using
a discovery and replication study design. Multivariable regression was used
to adjust for confounders including estimated leukocyte cell proportions
and population substructure. In secondary analyses, we assessed differential
methylation associations with anti-SSA, anti-Sm, and anti-RNP autoantibody
production.
Results: Significant associations between anti-dsDNA autoantibody
production and methylation status were replicated for 16 CpG sites
(Pdiscovery < 1.07 × 10
−7 and Preplication < 0.0029) in 11 genes. The adjusted
mean difference in methylation between the two autoantibody
subgroups ranged from 1 to 19%, and the adjusted odds ratio for anti-
dsDNA autoantibody production comparing the lowest with the highest
tertile of methylation ranged from 6.8 to 18.2. Differential methylation for
these sites was also associated with anti-SSA, anti-Sm, and anti-RNP
autoantibody production. All associated sites were less methylated in
autoantibody-positive compared with autoantibody-negative cases. Seven
of the 11 associated genes either induce interferon or regulate the
interferon signaling pathway. Among the differentially methylated genes
associated with the production of at least one autoantibody, cytokine and
interferon signaling pathways were the most represented.
Conclusions: Hypomethylation of interferon-related and other genes is
associated with autoantibody production among SLE cases. Differential
m e t h y l a t i o no ft h e s e1 1g e n e si na u t oantibody-positive SLE cases may
explain their recently reported associations with SLE risk, and the extent of
hypomethylation may influence disease manifestations.
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Background: Systemic lupus erythematosus (SLE) is a chronic autoimmune
disorder characterized by inflammation of multiple organ systems, loss of
tolerance to self-antigens, and dysregulated interferon responses. SLE is
both genetically and phenotypically heterogeneous, and we hypothesize
that this greatly reduces the power of overall case-control studies in SLE.
Increased circulating level of the cytokine interferon alpha (IFNa) is a stable,
heritable trait in SLE which has been implicated in primary disease
pathogenesis. Forty to 50% of patients have high IFNa, and high levels
correspond with clinical differences.
Methods: To study genetic heterogeneity in SLE, we performed a case-case
study comparing patients with high versus low IFNa in over 1,800 SLE cases.
Four hundred European ancestry cases formed the discovery GWAS set, and
1,443 cases from a large independent multi-ancestral replication cohort
were used to validate associations.
Results: In meta-analysis, the top associations in European ancestry were
PRKG1 rs7897633 (PMeta =2 . 7 5×1 0
−8) and PNP rs1049564 (PMeta =1 . 2 4×
10
−7). We also found evidence for cross-ancestral background associations
with the ANKRD44 and PLEKHF2 loci. These loci have not been previously
identified in case-control SLE genetics studies. Bioinformatic analyses
implicate these loci functionally in dendritic cells and natural killer cells, both
of which are involved in IFNa production in SLE.
Conclusions: As case-control studies of complex heterogeneous diseases
reach a limit of feasibility with respect to subject number and detectable
effect size, the study of informative pathogenic subphenotypes becomes
a highly attractive and efficient strategy for genetic discovery in complex
human disease.
Acknowledgements: SNK and YG-P contributed equally to the
manuscript.
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Background: NMNAT2 (rs2022013 located at intron 1) was identified as a
SLE risk locus in a European-derived population in a genome-wide
association study (GWAS). NMNAT2 (nicotinamide mononucleotide
adenylyltransferase 2) is expressed mainly in the brain, regulating energy
metabolism. Proximal to the SLE-associated NMNAT2 variant is SMG7,
encoding a component of the mRNA quality control pathway that
regulates spliceosomal machinery such as Sm and snRNP via alternative
s p l i c i n g .W ef i n em a p p e dt h eNMNAT2/SMG7 region in multiple ancestries
and explored functional consequences of the identified variants.
Materials and Methods: We genotyped/imputed 313 SNPs covering an
~550 kb NMNAT2/SMG7 region in 15,424 case-control subjects from
European-Americans (EA), African Americans, Asians and Amerindian/
Hispanics, assessed SNPs for association with SLE using a logistic regression
model adjusted for sex and ancestry, and used haplotype-based conditional
testing to distinguish independent associations. Quantitative real-time PCR
and luciferase reporter assays were used to examine allelic differences in
SMG7 expression and transcription activity. PBMCs from SLE patients (n =
13) were cultured with or without siRNA targeting SMG7, GAPDH (positive
control) or siRNA with a nontargeting sequence (NC, negative control), and
culture supernatants were measured by ELISA for levels of antinuclear
antibody (ANA) and cytokines/chemokines.
Results: We confirmed association at rs2022013 and identified two
independent signals in EA only: intron 1 of NMNAT2 tagged by rs12146097
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−10, OR = 1.38); and multiple SMG7 SNPs tagged by rs2275675
(P =5 . 7×1 0
−8, OR = 1.22). Expression quantitative trait locus data showed
SLE-risk alleles of NMNAT2/SMG7 variants consistently associated with
decreased mRNAs of SMG7, but not NMNAT2, in cell lines, suggesting SMG7
is a more likely risk gene for SLE. The rs2275675 risk allele was associated
with decreased SMG7 mRNAs dose dependently in PBMCs of 86 SLE
patients and 119 controls (P = 0.001 and 6.84 × 10
−8, respectively), and
reduced transcription activity in two transfected cell lines (P ≤ 0.004). SMG7
mRNA levels in PBMCs correlated inversely with ANA titers in 68 SLE
patients (P = 0.0089, r = −0.31). Compared with culture supernatants of SLE
PBMCs treated with NC-siRNA, those treated with SMG7-siRNA showed
increased ANA (P < 0.0001) and CCL19 (P = 0.0002; a ligand for CCR7
promoting movement/ interaction of B-Th cells and antibody production).
Conclusions: We confirmed the previous GWAS NMNAT2 association and
identified independent SMG7 association with SLE in an EA population.
The SLE-risk alleles are dose-dependently associated with decreased
SMG7 mRNAs, and SMG7 reduction increases ANA and CCL19 production
in PBMC cultures of SLE patients, sug g e s t i n gt h a td y s f u n c t i o ni nm R N A
surveillance conferred by SLE-associated SMG7 variants contributes to SLE
manifestations.
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Background: Systemic lupus erythematosus (SLE) is a complex disease that
is traditionally diagnosed and managed by specialists, typically
rheumatologists. Higher SLE prevalence in racial/ethnic minorities such as
American Indian/Alaska Native (AI/AN) people, often residing in areas with
less access to rheumatologists, may necessitate diagnosis and management
of SLE by primary care providers (PCP) in some cases. The purpose of this
analysis was to identify areas of potential difference between PCP and
specialist diagnosis and management of SLE in a population-based lupus
registry of AI/AN people.
Methods: All individuals with SLE meeting our inclusion criteria were
selected from the 2009 Indian Health Service lupus registry population.
Inclusion in this analysis was limited to individuals with a final diagnosis of
SLE made by a PCP or specialist (dermatologist, nephrologist or
rheumatologist) and documented in the medical record. Based on medical
record abstraction, SLE classification criteria were validated for each
individual. Testing for biologic markers of SLE and medication use at any
time during the course of the disease was also abstracted.
Results: Of the 320 patients identified with a documented physician
diagnosis of SLE, 71 had been diagnosed by a PCP. SLE diagnosis by a
specialist was associated with a higher median number of American
College of Rheumatology (ACR) classification criteria (5 vs. 2), a higher
percentage of patients meeting the definition of SLE by ACR criteria
(79% vs. 22%), the Boston Weighted criteria (82% vs. 32%), and an
abridged version of the Systemic Lupus International Collaborating
Clinics criteria (83% vs. 35%) (P < 0.001 for all comparisons).
Additionally, specialist diagnosis was associated with an increased
proportion with any testing for anti-double-stranded DNA antibody
(93% vs. 73%) and complement C3 and C4 (84% vs. 52%) documented
in the medical record (P <0 . 0 0 1f o ra l l ) .L a s t l y ,s p e c i a l i s td i a g n o s i sw a s
associated with ever treatment with hydroxychloroquine (86% vs. 64%,
P < 0.001) as documented in the medical record at any time during
their disease course.
Conclusions: Within the population studied, specialist diagnosis of SLE
was associated with a higher number of SLE classification criteria met, a
higher percentage of patients tested for biomarkers of disease, and a
higher percentage of patients ever treated with hydroxychloroquine.
A13
Racial discrimination and disease damage among African American
women with systemic lupus erythematosus
David H Chae
1, Christina M Drenkard
2, Tené T Lewis
3, S Sam Lim
2*
1School of Public Health, University of Maryland at College Park, College
Park, MD, USA;
2School of Medicine, Emory University, Atlanta, GA, USA;
3School of Public Health, Emory University, Atlanta, GA, USA
E-mail: sslim@emory.edu
Arthritis Research & Therapy 2014, 16(Suppl 1):A13
Background: African American women with SLE experience faster
progression and worse consequences of disease compared with their White
counterparts. This study sought to examine whether self-reported routine
experiences of discrimination, as a source of psychosocial stress, is
associated with disease damage among African American women with SLE.
Methods: Participants were 578 African American women in the Georgians
Organized Against Lupus study, a population-based cohort of SLE patients in
Atlanta, GA, USA. Disease damage was assessed using the Self-Administered
Brief Index of Lupus Damage (SA-BILD), a validated, patient-reported
measure of organ damage since the onset of SLE. Discrimination was
assessed using the Everyday Discrimination Scale, a widely used measure of
routine experiences of unfair treatment. Ordinary least-squares regression
analyses were used to examine the outcome of SA-BILD score by the
primary predictors: unfair treatment, racial discrimination attribution, and
their interaction, controlling for age and years since SLE diagnosis.
Results: The average SLE damage score in our sample was 2.3 (SD = 2.4),
and the mean years since initial diagnosis was 13.6 years (SD = 9.3). The
mean unfair treatment score was 1.92 (SD = 0.95), indicating that on average
participants reported experiencing each of the forms of unfair treatment
approximately once a year. A total of 159 participants (27.6%) reported not
experiencing any unfair treatment. Among participants reporting any unfair
treatment, most did not make an attribution of racial discrimination (n =2 5 8
compared with n = 146). Age (r = 0.23, P < 0.001) and years since diagnosis
(r =0 . 2 5 ,P < 0.001) were significantly correlated with SLE damage. Reports of
unfair treatment and making an attribution to racial discrimination were not
significantly associated with SLE damage. In multivariable regression analyses
controlling for age and years since diagnosis, we found a significant
interaction between unfair treatment and attributions to racial discrimination
(b = -0.52, SE = 0.24, P = 0.03). Greater unfair treatment attributed to
nonracial causes was associated with higher SA-BILD score, whereas unfair
treatment attributed to race showed an inverse association (Figure 1).
Conclusions: This study highlights the role that social stressors have in
contributing to the progression of SLE and is the first to examine whether
unfair treatment and racial discrimination are associated with disease damage
a m o n gA f r i c a nA m e r i c a nw o m e nw i t hS L E .C o n s i s t e n tw i t hf i n d i n g sf r o m
studies on discrimination and other health outcomes, these results suggest
more complex, interactive rather than direct associations with SLE damage,
with differential relationships being found between those who attributed
unfair treatment primarily to racial discrimination versus those who did not.
Figure 1(abstract A13) Predicted disease damage score by
attribution to racial discrimination among African American
women with systemic lupus erythematosus (SLE) reporting any
unfair treatment in the Georgians Organized Against Lupus (GOAL)
study (n = 578; 2011 to 2012).
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Background: Psychosocial and rehabilitation interventions are increasingly
used to attenuate disability and improve health-related quality of life (HRQL)
in chronic diseases, but are typically not available for patients with less
common diseases such as scleroderma or lupus. Conducting rigorous,
adequately-powered trials of nonpharmacological interventions for patients
with rare diseases is difficult. The Scleroderma Patient-centered Intervention
Network (SPIN) is an international collaboration of patient organizations,
clinicians, and researchers. The aim of SPIN is to develop a research
infrastructure to test accessible, low-cost self-guided online interventions to
reduce disability and improve HRQL for people living with scleroderma.
Once tested, effective interventions will be made accessible through patient
organizations partnering with SPIN.
Methods: SPIN will utilize a novel research design, the cohort multiple
randomized controlled trial (cmRCT) design, to collect longitudinal data
related to problems experienced by people living with scleroderma and as a
framework for developing, evaluating, and delivering psychosocial and
rehabilitation interventions. In the cmRCT design, patients consent to
participate in a cohort for ongoing data collection. The aim is to recruit
1,500 to 2,000 patients from centers across the world within a period of
5 years (2014 to 2018). Eligible participants are persons ≥18 years of age
with a verified diagnosis of scleroderma. In addition to baseline medical
data, participants will complete patient-reported outcome measures every
3 months. Upon enrolment in the cohort, patients will consent to be
contacted in the future to participate in intervention research and to allow
their data to be used for comparison purposes for interventions tested with
other cohort participants. Once interventions are developed, patients from
the cohort will be randomly selected and offered interventions as part of
pragmatic RCTs. Outcomes from patients offered interventions will be
compared with outcomes from trial-eligible patients who are not offered the
interventions.
Discussion: The use of the cmRCT design, the development of self-guided
online interventions, and partnerships with patient organizations will allow
SPIN to develop, rigorously test, and effectively disseminate psychosocial
and rehabilitation interventions for people with scleroderma. A similar
approach could be used to develop and test psychosocial and rehabilitation
interventions for people with lupus.
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Background: One of the strongest clinical associations with autoantibodies
(Ab) directed to components of the SSA/Ro-SSB/La ribonucleoprotein
complex is the development of congenital heart block (CHB) in an offspring.
Fetal disease is independent of maternal disease and often anti-Ro Ab are
first sought only because CHB has been identified. The first-time risk of
2% is 10-fold higher in women who have had a previous CHB child. Tissue
injury in the fetus is presumed to be dependent on the FcgR-mediated
transplacental passage of maternal IgG Ab. Despite attempts of large
multicenter studies to forestall disease by careful monitoring, irreversible
block and extensive myocardial injury have been documented within 7 days
of a normal rhythm and PR interval. In vivo and in vitro data support
that cardiac fibrosis may be consequent to macrophage Toll-like receptor
(TLR) signaling following ligation of the ssRNA complexed to the Ro protein.
TLR signaling and fibrotic endpoints may be abrogated by chloroquine (CQ),
which inhibits endosomal acidification. This in vitro observation was initially
“translated” to patients by evaluating the use of hydroxychloroquine (HCQ)
in an extensive case-control retrospective chart review of anti-Ro/La Ab
exposed fetuses of mothers with SLE enrolled in three databases. This
approach was followed by another study that addressed whether HCQ use
reduces the expected recurrence rate of CHB. The collective results were
highly encouraging.
Methods and results: Based on these studies we initiated an open-label
prospective study design using Simon’s two-step approach. HCQ at 400 mg
is initiated by 10 weeks following conception. Serial echocardiograms
(monitor PR interval) and evaluation of maternal and cord blood biomarkers
(HCQ levels, IFNa signatures, and Ab titers) are part of the protocol to
address maternal compliance, pathobiology and efficacy. The first stage has
been completed with 19 subjects and only one recurrence of CHB.
Future directions: Over the next 4 years, 35 subjects will be enrolled.
Ultimately, HCQ will be considered efficacious for the prevention of CHB if
fewer than six cases occur among a total of 54 subjects evaluated. A positive
result will probably change the management of all anti-Ro-positive women
who have had a previous child with CHB and illustrate the importance of
translational science. Perhaps most relevant to impact, a potential
prevention would justify screening of all pregnant women for anti-Ro
antibodies, particularly relevant since mothers of affected children are
frequently asymptomatic, a point critical to early pregnancy counseling.
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Background: The interferon regulatory factor 5 (IRF5) systemic lupus
erythematosus (SLE) risk loci is considered one of the most strongly and
consistently associated SLE loci identified. It has been detected using both
c a n d i d a t eg e n ea n dg e n o m e - w i d ea s s ociation studies. Haplotypes are
associated with increased, decreased, or neutral levels of risk for SLE and
have been shown to associate with functional changes in IRF5-mediated
signaling, including increased expression and elevated IFNa activity. The
majority of studies, however, were performed in peripheral blood
mononuclear cells and thus little is known of the function of IRF5 in specific
human immune cell populations. We are interested in understanding the
role of IRF5 in human B cells since previous studies in mice implicated a role
for IRF5 in effector B-cell development and function and murine models of
lupus lacking the Irf5 gene showed reduced ANA, glomerulonephritis and
pathogenic autoantibody production. Unfortunately, many of these studies
were complicated by the finding of a secondary mutation in the Dock2 gene
amongst Irf5
-/- mice. Recent findings from our laboratory indicate that IRF5 is
constitutively localized to the nucleus of human SLE memory B cells and
that activation of healthy donor B cells results in IRF5 nuclear localization,
suggesting a functional role for IRF5 in human B cells.
Methods: Human immortalized and primary B cells were utilized in this
study. Primary naïve B cells were obtained by informed consent at
University Hospital, Newark, NJ, USA under an approved IRB protocol, and
either mock stimulated or stimulated with anti-IgM and CpG-B for activation.
B-cell development, cytokine expression, autoantibody production and class
switch recombination were examined in the presence or absence of siRNAs
targeting IRF5 expression or peptide inhibitors targeting IRF5 nuclear
localization. An IRF5-mediated B-cell signature was also examined under
similar experimental conditions by ChIP-seq analysis.
Results: We find that IRF5 is indeed important for human B-cell effector
functions, including, but not limited to, cytokine expression, differentiation,
and autoantibody production, and have identified a pro-effector B cell gene
program that is regulated by IRF5.
Conclusions: These findings show for the first time that IRF5 is an
important regulator of human effector B-cell development and function
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would be expected to contribute significantly to SLE B-cell pathology.
These data provide initial insight into how inhibitors of IRF5 activation may
change SLE disease onset and/or progression.
A17
Platelet-derived microparticles serve as an important source of
autoantigens and discriminate between levels of disease activity in
systemic lupus erythematosus
Eric Boilard
1*, Vincent Bissonnette
1, Valérie Garceau
1, Ellie Aghdassi
2,
Nathalie Cloutier
1, Claudia Beaudoin
1,D a v yE n g
1, Stacey Morrison
2, Paul R Fortin
1,3
1Centre de recherche du CHU de Québec, Université Laval, Quebec City, QC,
Canada;
2Toronto Western Research Institute, Toronto, ON, Canada;
3CHU de
Québec - CHUL, Quebec City, QC, Canada
E-mail: eric.boilard@crchuq.ulaval.ca
Arthritis Research & Therapy 2014, 16(Suppl 1):A17
Background: Immune complexes (IC) are implicated in the pathogenesis
of several autoimmune diseases including systemic lupus erythematosus
(SLE). In SLE, submicron extracellular vesicles, called microparticles (MP),
are thought to serve as an antigenic surface promoting the deposition of
immunoglobulins and the formation of MP-associated immune complexes
(mpICs). However, the cellular origin of these mpICs is unknown and
whether they correlate with disease activity and particular clinical features
remains to establish.
Methods: The concentrations of mpICs in platelet-poor plasma from
193 women with SLE were determined using high-sensitivity flow cytometry.
Considering the recently revealed role of platelets in SLE, we further
scrutinized the contribution of platelets to mpICs formation. The platelet
and nonplatelet MPs and mpICs were tested for association with lupus
disease activity, damage, history of previous arterial disease, and the carotid
intima-media thickness and plaque area on ultrasound. To assess whether
disease activity and damage are associated with levels of MPs and mpICs,
univariate and multivariate negative binomial models were built using the
SLE disease activity index 2000 (SLEDAI-2K) and the SLICC/ACR damage
index (SDI) as outcome variables. In all models, the predictor variable was
the level of MPs or mpICs. When necessary, models were adjusted for
covariables such as age, disease duration, menopausal status, hypertension,
diabetes, anticoagulant or antiplatelet medication, antimalarial medication,
prednisone use, smoking status, and ethnicity.
Results: The clinical characteristics of the 193 women studied were: age
(mean (SD)) 46.3 (14.7) years; disease duration 18.5 (12.0) years; ethnicity
(% Caucasian) 57%; ever-smoker 34%; menopausal in 55%; hypertensive
30%; diabetic 5%; prescribed anticoagulant or antiplatelet medication
25%; prescribed antimalarial medication 74%; prescribed prednisone 44%.
Univariate analyses for activity revealed that platelet-derived mpICs, but
not mpICs from other cells, were associated with SLEDAI-2K. In the
multivariate model, this association remained significant (P =0 . 0 2f o r
annexin V
+ platelet mpICs and P = 0.0006 for annexin V
-platelet mpICs)
after adjusting for disease duration, hypertension and currently on
prednisone. There was no association between platelet mpICs and SDI.
Conclusions: Platelet-derived MPs are a major source of autoantigens
serving mpIC formation in SLE. Platelet-derived mpICs are associated with
lupus disease activity level on the SLEDAI-2K but not with damage. This is
the first report of an association between platelet mpICs and clinical marker
of activity in SLE and in any autoimmune disease. Platelet mpICs need to be
further considered as a possible biomarker of lupus disease activity.
Acknowledgements: This study was supported by the Canadian Institutes
of Health Research (to PRF and EB). EB is recipient of a fellowship from the
Fonds de Recherche du Quebec-santé.
A18
Vimentin is a dominant target of in situ humoral immunity in human
lupus tubulointerstitial nephritis
Marcus R Clark
*, Anthony Chang, Kichul Ko, Carole J Henry Dunand,
Scott Henderson, Dan Brandt, Natalya Kaverina, Vladimir Liarski,
Patrick C Wilson, Andrew J Kinloch
University of Chicago, Chicago, IL, USA
E-mail: mclark@medicine.bsd.uchicago.edu
Arthritis Research & Therapy 2014, 16(Suppl 1):A18
Background: In lupus nephritis (LuN), severe tubulointerstitial
inflammation (TII) predicts progression to renal failure. Severe TII is
associated with tertiary lymphoid neogenesis and in situ antigen-driven
clonal B-cell selection. The dominant autoantigen(s) driving in situ B-cell
selection in TII are not known.
Methods: Single CD38
+ or Ki-67
+ B cells were laser captured from seven
LuN biopsies. Twenty clonally expanded immunoglobulin heavy and light
chain variable region pairs were cloned and expressed as antibodies. Seven
more antibodies were cloned from flow-sorted CD38
+ cells from an eighth
biopsy. Antigen characterization was performed using a combination of
confocal microscopy, ELISA, screening protoarrays, immunoprecipitation and
mass spectrometry. Serum IgG titers to the dominant antigen were
determined in 45 LuN and 38 non-nephritic lupus samples using purified
antigen-coated arrays. Autoantigen expression was localized by
immunohistochemistry and immunofluorescence on normal and LuN kidney.
Results: Thirteen of 27 antibodies reacted with cytoplasmic structures,
four reacted with nuclei and none with dsDNA, Sm or RNP. Vimentin was
the only autoantigen identified by both mass spectrometry and on
protoarray. Eleven anticytoplasmic TII antibodies directly bound vimentin.
Vimentin was highly expressed by tubulointerstitial inflammatory cells,
and tested TII antibodies preferentially bound inflamed tubulointerstitium.
Finally, high titers of serum anti-vimentin antibodies were associated with
severe TII (P = 0.0001).
Conclusions: Vimentin, an antigenic feature of inflammation, is a dominant
autoantigen targeted in situ in LuN TII. This adaptive autoimmune response
probably feeds forward to worsen TII and renal damage.
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Background: Patients with systemic lupus erythematosus (SLE) often have
increased type I interferon levels (IFN-I) and activation of IFN-inducible
genes (IFN signature). Because IFN-I has a key role in both the innate and
adaptive immune responses, it is believed that heightened levels of this
cytokine and the many genes it regulates may underlie the immune
hyperreactivity and autoimmunity of SLE. The mechanism of IFN-I
hyperproduction in SLE is under intense study. An important lead has
emerged from our laboratory implicating the RIG-I antiviral pathway as a
possible cause. In particular, the mitochondrial adaptor protein MAVS is a
key intermediary in the RIG-I/MDA5 pathway, where viral RNA triggers a
conformational change in RIG-I, leading to MAVS activation with
subsequent IFN production. It has been reported that MAVS may form
large prion-like aggregates, which might stimulate IFN-I production in a
potent and prolonged fashion. We wondered whether such aggregates
might be detectable ex vivo in SLE patients, and whether they might play a
role in the sustained increased production of IFN-I.
Methods: Peripheral blood mononuclear cells (PBMCs) were isolated from
patients fulfilling ACR criteria for SLE, from healthy controls, and from
patients with rheumatoid arthritis (RA). Mitochondrial lysates were prepared
and MAVS aggregation was identified with a semi-denaturing agarose gel
and confirmed by confocal immunofluorescent microscopy.
Results: Twenty-two of 61 SLE patients showed clear MAVS aggregation,
with essentially all of their MAVS protein in a high molecular weight
aggregated form. None of the RA patients and only three of 33 healthy
controls had abnormal MAVS. Clinical data analysis revealed that 82.4%
MAVS-aggregate-positive SLE patients (mean age 46) had anti-SSA
antibodies, compared with 40% MAVS-aggregate-negative patients (mean
age 44), P < 0.01 by chi-square. 64.7% aggregation-positive patients had
active SLE disease (skin rash, arthritis, increased ESR, low C4, and active renal
disease), while only 10% of the aggregation-negative patients had active
disease.
Conclusions: Our findings are consistent with the notion that activation of
the RIG-I pathway through inappropriate or persistent MAVS aggregation
may lead to increased IFN-I production, immune stimulation, and systemic
autoimmunity in SLE.
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Background: Autoreactive B cells in SLE undergo autoantigen selection,
suggesting a requirement for germinal center follicular helper T (Tfh) cells
in their maturation. However, evidence for dysregulation of Tfh cells in SLE
and their potential contribution to disease remains unclear. Recently,
blood CXCR5
+ CD4 T cells, a heterogeneous pool consisting of functionally
distinct Th1-like, Th2-like, and Th17-like subsets, have been proposed to be
the circulating (blood) memory Tfh cells. We hypothesized that expanded
CXCR5
+ memory cells in the blood of human lupus patients promote B-cell
helper function reflecting the abnormal T-B-cell responses in secondary
lymphoid organs.
Methods and results: We characterized such cells in SLE patients by flow
cytometry and T-B coculture studies. SLE patients had significant expansion
of CXCR5
+ICOS
hiPD-1
hi CD4 T cells compared with controls. Such cells were
Bcl6
-, but robustly expressed IL-21 with a portion Ki-67
+, indicating their
functional activity. The blood cells were capable of providing blood-born
memory B cells with survival and differentiation signals to secrete isotype
switched Igs, including antinuclear antibodies.
Conclusions: We speculate that therapies which alter T-B collaboration in
lupus will abrogate their expansion, accompanied by reduced autoantibody
titers and improved disease activity in SLE patients. Our results suggest that
aberrant T-B collaboration in lupus is critical to disease pathogenesis and its
blockade is likely to be important therapeutically.
Acknowledgements: This work was supported in part by the Alliance for
Lupus Research and AR040072, AR44076, AR062842, and AR053495 (to JC).
STK was supported by a Research Scientist Development Award from the
American College of Rheumatology Research and Education Foundation and
by T32 AR07107.
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Background: Lupus nephritis affects 30 to 70% of systemic lupus
erythematosus (SLE) patients and its treatment remains insufficiently
effective and excessively toxic. Although biomarkers for nephritis are being
identified there is still no reliable way of predicting an impending renal
flare or determining which patients will respond to therapy. Because
human renal tissue cannot be obtained sequentially during remission and
relapse, animal models are often used to study progression of lupus
nephritis. To elucidate the molecular mechanisms involved in renal
inflammation during the progression, remission and relapse of nephritis
we performed a transcriptome analysis of renal tissue from two murine
lupus models, NZB/WF1 mice that develop proliferative glomerulonephritis
and NZM2410 mice that develop glomerulosclerosis with minimal
inflammation.
Methods: Kidneys from NZB/W F1 and NZM2410 mice were harvested at
intervals during their disease course or after remission induction with either
combination cyclophosphamide/costimulatory blockade or with BAFF
inhibition. Genome-wide expression profiles were obtained from microarray
analysis of perfused kidneys. Real-time PCR analysis for selected genes was
used to validate the microarray data. Comparisons between groups using
SAM, and unbiased analysis of the entire dataset using singular value
decomposition and self-organizing map were performed.
Results: Few changes in the renal molecular profile were detected in pre-
nephritic kidneys but a significant shift in gene expression, reflecting
inflammatory cell infiltration and complement activation, occurred at
proteinuria onset. Subsequent changes in gene expression predominantly
affected mitochondrial dysfunction and metabolic stress pathways.
Remission induction reversed most, but not all, of the inflammatory
changes and progression towards relapse was associated with recurrence
of inflammation, mitochondrial dysfunction and metabolic stress
signatures. Endothelial cell activation, tissue remodeling and tubular
damage were the major pathways associated with loss of renal function.
Conclusions: Immune cell infiltration and activation is associated with
proteinuria onset and reverses with immunosuppressive therapy but disease
progression is associated with renal hypoxia and metabolic stress. Optimal
therapy of SLE nephritis may therefore need to target both immune and
nonimmune disease mechanisms. In addition, the overlap of a substantial
subset of molecular markers with those expressed in human lupus kidneys
suggests potential new biomarkers and therapeutic targets.
Acknowledgements: RB and CCB contributed equally.
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Our laboratory has been studying the impact of low Blimp-1 expression on
dendritic cell function in SLE, analyzing both a mouse model of SLE in which
there is a deletion of Blimp-1 in CD11c dendritic cells (DC Blimp-1
KO mice)
and healthy individuals with the SLE risk allele of Blimp-1. This allele leads to
reduced Blimp-1 expression in dendritic cells. Low expression of Blimp-1
alters cytokine expression following TLR activation and antigen-processing
machinery. This leads to a highly distinct TCR repertoire in T-follicular helper
cells in DC Blimp-1
KO mice. Much of this phenotype is under estrogen
regulation. These data therefore provide an integrated explanation for
altered cytokines, autoantibodies and female predisposition in SLE.
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Background: Ultraviolet (UV) light exposure promotes the development of
cutaneous lupus and can induce flares of systemic lupus erythematosus.
Similarly, UV light can induce lupus in genetically prone strains of mice.
Nonobese diabetic (NOD) mice prone to autoimmune disease demonstrate
lupus-like disease after repeated combined UV irradiation and topical
application of TLR-7 agonist imiquimod (IMQ). In contrast, repeated topical
application of a Toll-like receptor (TLR) 7/8 agonist promotes psoriasiform
skin lesions in nonautoimmune mice such as Balb/c. The cellular and
molecular determinants of these processes are still unknown.
In this study we have compared the skin lesions induced by repeated topical
IMQ in Balb/C VS NOD mice. Gamma delta T cells are innate immune cells
that bridge innate and adaptive immunity in part by modulating dendritic
cell maturation. We have thus explored the role of gamma delta T cells in
the induction of psoriasis and SLE following topical TLR 7/8 agonist
application.
Methods: NOD and Balb/C mice received 70 mg topical IMQ 5% cream on
shaved back skin daily for 5 days. Skin, draining lymph nodes (LNs) and sera
were obtained for histological and serological analysis.
Results: Balb/c mice but not NOD mice developed thickened erythematous
and scaly skin lesions similar to psoriasis. Histological examination revealed
acanthosis, parakeratosis and papillomatosis resembling psoriasis in Balb/c
mice but not in NOD mice. IL-17-producing T cells were increased in the
dermis and skin draining LNs of Balb/C mice after 5 days topical IMQ,
whereas the frequency of IFNg-producing gamma delta T cells was higher in
NOD mice. Serum collected 24 hours after treatments with IMQ showed
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IMQ increased the relative frequencies of granulocytes in the skin and skin
draining LNs in Balb/c but not in NOD mice. In contrast, the frequency of
macrophages was increased in NOD skin.
Conclusions: Our work suggests that a predominant Th1 response,
orchestrated in part by gamma delta T cells in response to TLR7/8
agonism in the skin, may predispose to SLE-like autoimmunity.
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Background: Neutrophils have long been recognized as important
contributors of inflammation and tissue destruction in systemic lupus
erythematosus (SLE). The LE cell (engulfment of antibody-opsonized nuclear
material by neutrophils) was for decades regarded as the hallmark of SLE.
With the discovery of neutrophil extracellular traps (NETs), the extrusion of
intracellular modified DNA and histones to trap microbes, as well as the
highly proinflammatory neutrophil subset named low-density granulocytes
(LDGs) during the last decade, interest in the neutrophil in SLE has seen a
renaissance. However, there are data to suggest that neutrophils can play
important roles in protection against, induction of and resolution of
inflammation.
NETs were originally described as chromatin bound to granular and
cytoplasmic molecules. However, today we know that the composition of
NETs is highly dependent on the inducing stimulus and may contain
characteristic lupus autoantigens such as DNA and chromatin. In SLE, LDGs
spontaneously release NETs ex vivo,a n din vitro, and autoantibodies directed
against RNP induce release of neutrophil DNA able to subsequently mediate
interferon (IFN)-alpha production by plasmacytoid dendritic cells (pDCs). Due
to the suggested role of NETs in exposing autoantigens and supporting type
I IFN production, several attempts have been made to inhibit NETosis in
murine lupus models. So far, two main pathways - citrullination and
oxidation - have been targeted. Whereas inhibition of the citrullination
pathway (PAD4) reduced development of nephritis, deficiency in oxidation
(Nox2) resulted in worsened lupus-like disease.
Methods and results: We have studied the interplay between neutrophils
and peripheral blood mononuclear cells (PBMCs) with regard to production
of inflammatory mediators in response to nucleic acid-containing immune
complexes (ICs). As demonstrated previously, RNA-containing ICs are
efficient inducers of type I IFNs by either isolated pDCs or pDCs in PBMCs.
However, when NETosis was induced by SLE ICs in the presence of PBMCs,
production of type I IFNs, as well as other inflammatory cytokines, was
markedly inhibited. This somewhat surprising finding may be explained by
an inability of NETs to induce substantial inflammation in blood cultures due
to the recently demonstrated anti-inflammatory effects through trapping
and degradation of proinflammatory cytokines. In addition, neutrophils may
compete for IC binding and internalization.
Conclusions: We thus propose that in a physiological setting with the
presence of both neutrophils and PBMCs, neutrophils may act as a sentinel
capable of directing proinflammatory or anti-inflammatory responses
depending on the presence of other cell types, spillage of NETs and other
factors.
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Background: Oxidative stress is increased in systemic lupus erythematosus
(SLE), and it contributes to immune system dysregulation and fatal
comorbidities. Mitochondrial dysfunction in T cells promotes the release of
highly diffusible inflammatory lipid hydroperoxides, which spread oxidative
stress to other intracellular organelles and through the bloodstream. In T cells
from patients with SLE and animal models of the disease, glutathione, the
main intracellular antioxidant, is depleted and the mechanistic target of
rapamycin (mTOR), serine/threonine protein kinase, undergoes redox-
dependent activation. In turn, reversal of glutathione depletion by application
of its amino acid precursor, N-acetylcysteine, blocks mTOR activation and
improves disease activity in lupus-prone mice and patients with SLE. While
mTOR has been also recognized as an effector of T-cell lineage development,
its role in autoimmunity and disease activation remain unclear.
Methods: Here, we prospectively examined mitochondrial dysfunction and
mTOR in PBL relative to SLEDAI and BILAG disease activity indices during
274 visits of 59 patients and 54 healthy subjects matched for each patient
blood donation. A total of 212 metabolic biomarkers and traditional
biomarkers, anti-DNA, C3, and C4, were evaluated by partial least-square
discriminant analysis (PLS-DA). False discovery rate (FDR) P values were
determined for each contributing biomarker and considered significant at
P < 0.000236 with correction for multiple comparisons (0.05/212).
Medication use was compared between patient groups exhibiting flare and
remission with chi-square and Fischer’s exact tests.
Results: PLS-DA identified 15 of 212 parameters that accounted for 70.2%
of the total variance and discriminated lupus and control samples (P <
0.0005); increased mitochondrial mass of CD3
+/CD4
-/CD8
- double-negative
(DN) T cells (P =1 . 1×1 0
-22) and FoxP3 depletion in CD4
+/CD25
+ Tc e l l s
were top contributors (P =6 . 7×1 0
-7). Prominent necrosis and mTOR
activation were noted in DN T cells during 15 visits characterized by flares
(SLEDAI increase ≥4) relative to 61 visits of remission (SLEDAI decrease ≥4).
mTOR activation in DN T cells was also noted at preflare visits of SLE
patients relative to those of stable disease or healthy controls. DN lupus
T cells showed increased production of IL-4, which correlated with depletion
of CD25
+/CD19
+ B cells. Rapamycin treatment in vivo reduced SLEDAI and
BILAG, blocked the IL-4 production and necrosis of DN T cells, increased the
expression of FoxP3 in CD25
+/CD4
+T cells, and expanded CD25
+/CD19
+
Bc e l l s .
Conclusions: These results identify mTOR activation to be a trigger of IL-4
production and necrotic death of DN T cells, predictor of disease flares, and
effective target for treatment in patients with SLE.
Acknowledgements: This work was supported in part by grants AI072648
and AT04332 from the National Institutes of Health, the Alliance for Lupus
Research, and the Central New York Community Foundation [http://
ClinicalTrials.gov:NCT00775476, http://ClinicalTrials.gov:NCT00779194].
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Background: Cutaneous manifestations are very common in systemic lupus
erythematosus (SLE). TNF-like weak inducer of apoptosis (TWEAK) is a
soluble cytokine member of the TNF superfamily that binds to a sole
receptor, Fn14. TWEAK/Fn14 signaling is involved in cell survival, apoptosis,
cytokine production, and angiogenesis, and as such has been found to be
important in both tissue repair and inflammatory diseases. Whether TWEAK
is involved in autoimmune skin disease is not known.
Methods: To evaluate a possible role for TWEAK in the pathogenesis of
cutaneous lupus, we generated a lupus-prone mouse strain, MRL-lpr/lpr
(MRL/lpr), deficient in Fn14, and evaluated the development of skin disease
in this strain as compared with age and gender-matched MRL/lpr mice.
In vitro studies using a keratinocyte cell line, PAM212, were performed to
evaluate the effects of TWEAK and ultraviolet B (UVB) irradiation on
apoptosis and cytokine production.
Results: We found that lupus-prone MRL/lpr mice deficient for Fn14
(Fn14KO) had markedly attenuated cutaneous disease as compared with
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acanthosis and follicular plugging, and there was decreased infiltration of
T cells and macrophages as compared with Fn14WT mice. In vitro, TWEAK
treatment of murine keratinocytes stimulated the secretion of RANTES
(via Fn14), and promoted apoptosis. Parthenolide decreased production
of RANTES, indicating that this effect of TWEAK is mediated via NF-B.
Ultraviolet light, specifically UVB, is recognized as a potent trigger of
cutaneous lupus. We found that TWEAK co-treatment exacerbates UVB
light-induced keratinocyte apoptosis and increases the amount of RANTES
secreted, when compared with cells treated with UVB alone. These
synergistic effects of TWEAK+UVB on keratinocytes were probably due to
upregulation of Fn14 expression by UVB.
Conclusions: O u rd a t as t r o n g l yi m p l i c a t eTWEAK/Fn14 signaling in the
pathogenesis of the cutaneous manifestations of lupus.
Acknowledgements: The authors would like to thank Dr Nancy Bigley
(Wright State University, Dayton, OH, USA) for the kind gift of PAM212
keratinocytes.
A27
Phenotypic consequences of TLR7-driven interferon and
proinflammatory cytokine production in lupus
Westley H Reeves
*, Haoyang Zhuang, Yuan Xu, Shuhong Han, Hai Wang,
Lijun Yang
University of Florida, Gainesville, FL, USA
E-mail: whreeves@ufl.edu
Arthritis Research & Therapy 2014, 16(Suppl 1):A27
Background: Although type I interferons (IFN-I) are involved in the
pathogenesis of SLE, clinical heterogeneity of the disease is not fully
explained by IFN-I overproduction. We investigated the relative importance
of IFN-I versus proinflammatory cytokine production downstream of TLR7
in a murine lupus model and in SLE patients.
Methods: TLR7-mediated experimental lupus was induced in wild-type and
knockout mice by pristane and the expression of IFN-I stimulated genes and
numbers of plasmacytoid dendritic cells (pDCs) and inflammatory (Ly6C
hi)
monocytes were assessed by PCR and flow cytometry, respectively.
Production of TNFa and other proinflammatory cytokines was evaluated by
intracellular staining. In parallel, we studied production of these cytokines in
the bone marrow (BM) of SLE patients.
Results: SLE patients’ BM exhibited striking death of niche and
hematopoietic cells associated with local TNFa overproduction. BM from
mice with pristane-induced lupus showed similar abnormalities. TNFa was
produced mainly by BM neutrophils, many of which contained
phagocytosed nuclear material (LE cells). TNFa production was abolished
in TLR7
-/- and μmt mice but was unaffected by C3 deficiency. Production
was restored in μmt mice by infusing normal plasma, consistent with
opsonization of endogenous TLR7 ligands by immunoglobulin. Although
autoantibody production and glomerulonephritis are abolished in
interferon receptor (IFNAR)
-/- mice, both wild-type and IFNAR
-/- mice
developed anemia and BM hypocellularity following pristane treatment.
These manifestations were absent in TLR7
-/- and TNFa
-/- mice, indicating
that the anemia is TNFa mediated. Unexpectedly, although TNF inhibitors
can induce lupus manifestations, TNFa
-/- mice did not develop
autoantibodies spontaneously. However, although IFN-I levels were
comparable in untreated TNFa
-/- and B6 mice, TNFa
-/- mice had increased
circulating pDCs and “pDC-like” cells, enhancing their potential to make
IFN-I. When treated with pristane, TNFa
-/- mice developed more severe
lupus than controls with increased levels of anti-Sm/RNP autoantibodies,
IFN-I, pDCs, and peritoneal inflammatory (Ly6C
hi) monocytes.
Conclusions: Although autoantibodies and glomerulonephritis are TLR7/
IFN-I dependent, lupus-associated BM abnormalities were TLR7/TNFa
driven, but IFN-I independent. TNFa had a downregulatory effect on pDC
numbers and TNFa-deficient mice exhibited an enhanced potential to
produce IFN-I in response to TLR7 ligands. Our data suggest that the
clinical manifestations of lupus reflect the complex interplay of cells
producing IFN-I (causing autoantibodies and nephritis) and TNFa (causing
hematologic involvement and arthritis). Engagement of TLR7 by RNA
ligands released by dead cells may be a central defect in lupus, whereas
the balance of IFN-I versus TNFa production may help determine the
disease phenotype.
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Background: Pregnant patients with SLE are at increased risk of placental
insufficiency and preeclampsia, disorders associated with angiogenic factor
imbalance. IFNa, a critical element in SLE pathogenesis, is a potent
antiangiogenic factor. In a case-control longitudinal study of lupus
pregnancies from PROMISSE (Predictors of Pregnancy Outcome: Biomarkers
In Antiphospholipid Antibody Syndrome and Systemic Lupus Erythematosus),
we investigated whether elevated IFNa early in pregnancy might be
associated with poor pregnancy outcomes.
Methods: Each of 28 SLE patients with poor pregnancy outcome was
matched to an SLE patient with an uncomplicated pregnancy and to a
pregnant healthy control. Serum samples obtained monthly through
pregnancy were assayed for IFNa activity using a reporter cell assay, and for
antiangiogenic factor, sFlt1, and proangiogenic factor, placenta growth
factor (PlGF). Human umbilical vein endothelial cells (HUVEC) were cultured
in the presence of IFNa and/or sFlt1, and gene expression assessed by q-RT
PCR. The effect of IFNa and sFlt1 on endothelial-trophoblast interactions
was assessed in an in vitro model of spiral artery transformation in which the
capacity of human first trimester extravillous trophoblasts to stabilize
endometrial endothelial cell tube structures is measured.
Results: Compared with SLE patients with uncomplicated pregnancies,
those with preeclampsia had increased IFNa before clinical symptoms.
Nonautoimmune patients destined for preeclampsia did not have
increased IFNa. In SLE patients with low IFNa, marked angiogenic
imbalance (higher sFlt1, lower PlGF and higher sFlt1/PLGF ratios) precedes
maternal manifestations of preeclampsia, whereas in SLE with high IFNa,
preeclampsia occurs without evidence of systemic angiogenic imbalance.
To investigate this result, we treated HUVEC with exogenous sFlt1 and
IFNa. Treatment with sFlt1 induced the expression of sFlt1 mRNA, and
IFNa dramatically amplified the endothelial response to sFlt1, leading to a
local positive feedback loop. Furthermore, in an in vitro model of spiral
artery transformation, only IFNa and sFlt1 together disrupted the ability of
trophoblast cells to remodel endothelial tube structures.
Conclusions: Our studies identify a new mechanism by which IFNa induces
an antiangiogenic milieu in the vasculature leading to inadequate spiral
artery remodeling and poor placentation early in pregnancy and maternal
endothelial dysfunction presenting as preeclampsia later in pregnancy. They
suggest that elevated IFNa may contribute to the pathogenesis of
preeclampsia in some pregnant women with SLE.
Acknowledgements: Supported by NIAMS [http://ClinicalTrials.gov:
NCT00198068].
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Background: Antibodies produced by B lymphocytes provide key functions
that help protect against pathogens while recent studies show there can
also be roles in maintaining homeostasis. Substantial levels of spontaneously
arising IgM antibodies recognize cross-reactive oxidation-associated
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these natural antibodies can enhance efficiency of apoptotic clearance by
innate immune cells, and also suppress proinflammatory responses. In vivo
administration can block the development of the inflammatory autoimmune
disease and enhance survival of lupus-prone mice. These inhibitory
responses are linked to anti-inflammatory signaling with nuclear localization
of MAPK phosphatase-1, a factor known to also mediate glucocorticoid
suppression of immune responses.
Methods: To investigate the relevance to clinical SLE disease we analyzed
the relationships between NAb levels with lupus disease activity, tissue
injury and cardiovascular (CV) effects in two independent lupus cohorts.
Results: In 120 SLE patients from the Hopkins cohort, levels of IgM anti-PC
were significantly higher in patients with low disease activity and with less
organ damage by SELENA SLEDAI, as well as by the physician’s evaluation
and the SLICC damage score. Importantly, IgM anti-PC levels were also
significantly higher in patients without histories of clinical CV events (that is,
MI, angina or stroke). In 105 SLE patients from the NYU cohort, we found
that subclinical CV disease, as detected by carotid ultrasound, correlated
with lower levels of IgM anti-PC (P = 0.004), and also lower ratios of IgM
anti-PC/total IgM, compared with patients without plaque (P =0 . 0 2 ) .T h e
IgM anti-PC/total IgM association remained significant after adjusting for
age, cholesterol and hypertension. Adiponectin and sE-selectin were
significantly elevated in patients with plaque, and statistical models showed
that combining adiponectin, sE-selectin and IgM anti-PC/total IgM was
better for predicting plaque than either test alone.
Conclusions: Our clinical surveys have contributed to emerging evidence
that regulatory anti-PC antibodies may oppose the influence of pathogenic
lupus autoantibody ICs. Our data suggest that levels of anti-PC IgM
antibodies may serve as a surrogate biomarker for vascular damage
associated with subclinical atherosclerosis, and could have clinical
applicability for monitoring and predicting relative risk in SLE patients.
Acknowledgements: Studies of the Hopkins cohort were part of a
collaboration with Dr Michelle Petri. Studies of the NYU cohort are part of a
collaboration with Jill Buyon, Robert Clancy and labmates.
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Although tyrosine phosphatases have been well documented to be involved
in the control of the immune system, serine/threonine phosphatases have
not been assigned a similar role. Studies in patients with systemic lupus
erythematosus (SLE), however, revealed that the protein, mRNA and catalytic
activity of a serine/threonine phosphatase A (PP2A) are increased in T cells.
More importantly, PP2A has a master role in the aberrant biochemistry of
SLE T cells because it: dephosphorylates pCREB and deprives an enhancer
from various genes; dephosphorylates Elf1 and accounts for decreased
expression of CD3ς and increased expression of FcRg; activates
(dephosphorylates) SP1 and promotes the expression of SP1-dependent
genes such as CREM; and suppresses the activity of DNMT1 and promotes
gene demethylation.
Gene function studies have revealed that promoter and intronic SNPs, along
with epigenetic modifications of the promoter region, account for the
expression of increased amounts of PP2A in SLE patients.
A mouse overexpressing PP2Ac in T cells does not develop autoimmunity
but it displays increased amounts of IL-17 in the blood and develops florid
glomerulonephritis when challenged with an anti-GBM antibody. Lastly,
PP2A is involved in the epigenetic control of expression of IL-17.
Besides the increased expression of the catalytic subunit of PP2A, several
regulatory (B) subunits appear to be abnormally expressed in SLE patients.
Specifically, Bb’ is decreased in one-half of SLE patients and accounts for
defective IL-2 deprivation T-cell death, thus prolonging the survival of
autoreactive T cells.
In conclusion, the catalytic and regulatory subunits of PP2A are abnormally
expressed in SLE and contribute to aberrant T-cell function and organ
damage. The fact that PP2Ac controls several downstream events urges its
therapeutic targeting. The findings that PP2A B subunits control distinct T-cell
function will enable corrective actions without the fear of collateral damage.
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Background: The development of point-of-care diagnostics (POCD) is
prompted by the global burden of diseases attended by high morbidity
and mortality when the diagnosis is delayed. POCD are designed to bring
diagnostic tests immediately accessible to the site of patient care. In
general terms, these devices are simple to use, economical, have high
specificity and have a short turnaround time, enabling rapid clinical
decisions. Contemporary POCD devices target blood glucose, coagulation,
cardiac markers, infectious diseases, pregnancy and cholesterol testing.
Systemic lupus erythematosus (SLE) is a suitable target for POCD because
it can present with a variety of rapid-onset and life-threatening features,
and is characterized by a number of well-defined disease-specific
biomarkers. Clinical scenarios where POCD would benefit the management
of SLE include CNS lupus (psychosis, encephalitis, stroke, seizures),
transverse myelitis, acute renal failure, pulmonary hemorrhage and
pneumonitis, cytopenias (thrombocytopenia, anemia, neutropenia,
leukopenia), catastrophic antiphospholipid syndrome, cardiac tamponade
and infarction, fetal heart block, mesenteric vasculitis and pancreatitis.
Methods: In collaboration with Dr Fooke Laboratorien GmbH (Neuss,
Germany) we are developing and beta testing a lateral flow POCD that
detects anti-dsDNA within 20 minutes after application of 10 μls e r u m .
Twenty preselected SLE sera and age and gender-matched controls were
tested. Interpretation of the test results were performed by direct visual
observation or by densitometry using a portable lateral flow assay reader.
Semi-quantitative results were expressed as relative units.
Results: When compared with results of the conventional Crithidia lucilliae
assay, the POCD had a sensitivity of 90% and a specificity of 100%. Further
testing to establish sensitivity, specificity and receiver operator characteristic
in unselected SLE and control sera are underway.
Conclusions: Pilot data using this lateral flow POCD were favorable and had
similar characteristics as those recently published by N Offermann in the
Journal of Immunological Methods. The features of future POCD are based on
advanced diagnostic platforms such as lateral flow, novel nanomaterials and
microfluidics (lab on a chip), which are miniaturized and portable, have high
specificity and design, are multiplexed and high throughput, and are
standardized.
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Background: The molecular events occurring within the kidney at diagnosis
of lupus nephritis (LN) are incompletely understood. Despite use of intense
immunosuppression, response rates are disappointingly low. We postulate
that characterizing these events will lead to biomarker discovery and guide
therapeutics. As proof of concept we evaluated the molecular pathology of
LN kidney biopsies in a Latino cohort.
Methods: We studied 19 pairs of proliferative LN biopsies and four
normal control biopsies using Nanostring RNA technology. All patients
had at least two biopsies with the first at LN flare and the second after a
median follow-up of 8 months. Based on clinical parameters, five patients
achieved complete remission (CR), 10 partial remission (PR) and four had
no response (NR) by the time of repeat biopsy. A panel of 511 immune-
response genes was analyzed for each biopsy. Data were log2
transformed and quartile normalization was used to normalize data
across samples. A linear model was used to compare the four groups
(normal/CR/PR/NR) at baseline and a paired t test was used to compare
baseline expression data at baseline and follow-up for each patient.
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Page 12 of 23Transcripts were considered to be differentially expressed if they differed
by at least twofold and if P < 0.01.
Results: At flare, three transcripts were uniquely expressed in CR, seven
transcripts in PR, and 20 transcripts in NR when compared with normal.
When compared with NR flares, CR flares showed increased MME, FADD,
and CD274 and decreased ITGB2 and C1S expression. Change in transcript
expression from initial to repeat biopsy was compared within each group
and between groups. From biopsy 1 to biopsy 2, the CR group showed
increased NCAM1 and decreased ILRL1 and FKBP5 expression. The NR
group showed increased IL1RAP and CD5 and decreased C7, IL28B, and
IL12RB1 expression. When compared with the CR group, the NR group
showed increased IL17a, NOS2, FCAR and IL1RAP and decreased NCAM1,
C7, and IL28B expression. NR flares had significant activation of T-cell and
B-cell receptor signaling, IL-10, STAT3, and TNF-R pathways when
compared with CR flares. Compared with NR flares, CR flares showed
significant activation of T-cell regulation, antigen presentation, and
apoptotic pathways.
Conclusion: The results of this study suggest that the molecular
characteristics of responders are different than nonresponders. These data
imply that molecular analysis of LN biopsies may provide prognostic
information and guide choice of therapy.
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Background: Systemic lupus erythematosus (SLE) US Hispanic patients
with a large Amerindian ancestral background have been found to have
poor outcomes. Similar observations have been made in the mixed
population of Latin America. We are now comparing and contrasting
selected sociodemographic and clinical features and outcomes of lupus
patients from these two groups.
Methods: SLE US Hispanic patients (European and Amerindian ancestry)
from the LUMINA cohort (Lupus in Minorities: Nature vs. Nurture) and Latin
American Mestizo patients from the GLADEL cohort (Grupo LatinoAmericano
De Estudio de Lupus (Latin American Group for the Study of Lupus))
constitute the study population. Only patients who fulfilled four of the 1997
ACR criteria were included. Diagnosis time was time to the fourth criterion.
Demographic and clinical data from these patients were extracted. When
the ascertainment method for a specific variable was different in both
cohorts, this has been noted. All variables were then compared using
descriptive statistical tests. Adjustment for disease duration was done when
indicated using either a Poisson regression or logistic regression, as
appropriate.
Results: Salient features for these two patient groups are presented in
Table 1. Some of the differences observed in terms of the socioeconomic
features could be due to the different methods of ascertainment.
Conclusions: Patients in both cohorts exhibited active disease, with renal
involvement and damage being frequent, and overall damage accruing
rapidly; however, the US Hispanic patients exhibited a higher mortality.
These two patient groups were also of low SES. These data suggest that
these two populations share an underlying genetic background which
coupled with a poor SES places them at increased risk for severe lupus with
unfavorable short, intermediate and long-term outcomes. The less favorable
mortality experience of the US Hispanics deserves to be further examined.
Acknowledgements: Thanks to LUMINA and GLADEL investigators on
whose behalf this work is being presented.
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Background: Chronic obstructive pulmonary disease (COPD) has been
recently recognized as an inflammatory disease. A recent Swedish hospital-
based study found an increased risk of COPD in patients with a number of
autoimmune conditions including systemic lupus erythematosus (SLE). We
wonder whether the risk is also present in SLE patients from the general
population. The objective was to assess the future risk of newly recorded
COPD cases among incident SLE cases compared with controls from the
general population using physician billing and hospitalization data that
cover the entire province of British Columbia (BC), Canada.
Methods: Our data include all health professionals and hospital visits
covered by the comprehensive provincial medical services plan (1990 to
2010) and all dispensed medication (1996 to 2010), for all BC residents.
We conducted a retrospective matched cohort (1996 to 2010) study
Table 1(abstract A33) Salient features of US Hispanic SLE patients from LUMINA and Latin America Mestizo patients
from GLADEL (at diagnosis or at last visit)
Characteristic LUMINA (n = 114) GLADEL (n = 619) P value
Age, mean (SD) 31.3 (12.2) 29.4 (12.6) 0.138
Gender (female), n (%) 106 (93.0) 546 (88.2) 0.135
Disease duration (years), mean (SD) 6.1 (4.3) 4.5 (4.6) <0.001
Low SES
a, n (%) 42/107 (39.3) 391 (63.2) <0.001
Health insurance, n (%) 56/112 (50.0) 466/615 (72.5) <0.001
Acute onset, n (%) 34 (29.8) 151 (24.4) 0.220
ACR criteria number
b, mean (SD) 6.8 (1.6) 6.3 (1.5) 0.069
Disease activity (moderate-high)
c, n (%) 78/92 (84.8) 438/493 (88.8) 0.268
Renal disorder, n (%) 60 (52.6) 370 (59.8) 0.155
SDI score at last visit
b, mean (SD) 2.3 (2.6) 1.7 (1.7) <0.001
Renal damage (per SDI, at last visit)
d, n (%) 37 (32.5) 184 (29.7) 0.559
Deceased
d, n (%) 21 (18.4) 35 (5.7) <0.001
SES, socioeconomic status; ACR, American College of Rheumatology; SDI, SLICC (Systemic Lupus International Collaborating Clinics) Damage Index.
aSES defined
as being below the Federally-defined poverty line for LUMINA and as per the Graffar method for GLADEL.
bAfter adjusting for disease duration in a Poisson
regression model.
cDefined as a SLAM (Systemic Lupus Activity Measure) >7 for LUMINA and a SLEDAI (Systemic Lupus Erythematosus Disease Activity Index) >4
for GLADEL.
dSignificant after adjusting for disease duration using a Poisson regression model (for the SDI) and logistic regression for mortality
Arthritis Research & Therapy 2014, Volume 16 Suppl 1
http://arthritis-research.com/supplements/16/S1
Page 13 of 23among patients satisfying at least one of the following validated criteria:
one diagnostic code for SLE (ICD-9-CM = 710.0) on at least two visits
within a 2-year period by a nonrheumatologist physician; one ICD-9 code
by a rheumatologist or from hospitalization; and absence of a prior SLE
diagnosis between 1990 and 1995. Ten controls matched by birth year,
sex and calendar year of exposure were randomly selected from the
general population for each case. Outcome: we used a validated criteria
to define COPD (first ICD-9-CM: 491, 492, 496, 493.2, or ICD-10-CM J43 or
J44) from hospitals or death certificates. We estimated relative risks (RRs)
by comparing SLE cases with age-matched, sex-matched and entry-time-
matched comparison cohorts, adjusting for confounders. Sensitivity
analyses were conducted to assess for unmeasured confounders.
Results: Among 4,486 individuals with incident SLE, 96 developed COPD
(incidence rate = 4.96 per 1,000 person-years) (Table 1). The age-matched,
sex-matched and entry-time matched RRs were significantly increased in
the SLE cohort when compared with controls (RR 2.31, 95% CI 1.83 to
2.89). After adjusting for covariates the results remained statistically
significant. The risk of developing COPD was highest within the first year
following the diagnosis of SLE, decreasing over time and remaining
significant up to 4 years after diagnosis. Our results remained statistically
significant after adjusting for the potential impact of an unmeasured
confounder (adjusted RRs ranging between 1.58 and 1.98 in all sensitivity
analyses).
Conclusions: This is the first general population-based study indicating a
twofold increased risk of COPD in patients with SLE. The risk of developing
COPD was highest within the first year, declining thereafter, suggesting the
potential pathogenic role of inflammation in the development of COPD.
Acknowledgements: Research funded by an operating grant from the
Canadian Arthritis Network/The Arthritis Society and the BC Lupus Society
(Grant 10-SRP-IJD-01).
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Background: Patients with systemic lupus erythematosus (SLE) experience
an increased risk of cancer, which is particularly driven by hematological
malignancies. Our objective was to determine whether certain factors
(demographics, SLE duration and calendar year) were associated with cancer
risk in SLE, relative to the general population, using a large multicenter
clinical cohort.
Methods: We present detailed analyses of a multisite international SLE
cohort (30 centers, 16,409 patients). Cancers were ascertained by registry
linkage. Standardized incidence ratios (SIR; ratio of observed to expected
cancers) were calculated for overall and for hematological cancer risk,
representing the relative risk of cancer for SLE patients, versus the age, sex,
and calendar-year-matched general. We used Poisson hierarchical regression
to assess for potential independent effects of the factors examined (sex,
race/ethnicity, age group, SLE duration, calendar-year period) on the SIRs
Table 1(abstract A34) Risk of incident COPD according to SLE status
SLE (n = 4,486) Non-SLE (n = 47,190)
COPD cases, n 96 419
Incidence rate/1,000 person-years 5.0 2.1
Age-matched, sex-matched, and entry time-matched RRs (95% CI) 2.3 (1.8 to 2.9) 1.0
<1 year of disease duration 6.1 (4.0 to 9.2) 1.0
1to 4.9 years of disease duration 1.7 (1.2 to 2.5) 1.0
5+ years of disease duration 1.5 (0.9 to 2.3) 1.0
Multivariable RR (95% CI) 2.0 (1.5 to 2.6) 1.0
Table 1(abstract A35) Results of adjusted multivariate
regression to determine independent effect of variables
on SIR* estimates for cancer in SLE
Adjusted effects
a 95% confidence interval
Female sex 1.00 0.77 to 1.30
Race/ethnicity
White Reference group
Black 0.75 0.58 to 0.97
Asian 1.18 0.85 to 1.62
Age
<40 Reference group
40 to 59 0.72 0.55 to 0.94
60+ 0.55 0.42 to 0.73
SLE duration
<5 years Reference group
≥5 years 0.74 0.61 to 0.89
Calendar-year period
<2000 Reference group
≥2000 0.95 0.79 to 1.15
aVariables adjusted concomitantly for all others (sex, race/ethnicity, age, SLE
duration, calendar-year period).
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Page 14 of 23among the SLE cohort members. The hierarchical nature of the model
allowed for differences in effects from one country to the next.
Results: In adjusted analyses (Table 1), we demonstrated lower SIR
estimates for overall cancer risk, in black versus white SLE patients, in SLE
patients of older versus younger age, and for patients with SLE duration of
5 years or more (versus lower duration). Female sex and calendar year were
not clearly associated with any differences in the SIR estimates for SLE
patients. Regarding hematological cancer specifically, SLE duration of 5 years
or more again appeared to be associated with lower SIR estimates.
Conclusions: Although cancer risk in SLE is increased relative to the general
population, patients most at risk appear to be those of white race/ethnicity,
younger age, and of shorter SLE duration.
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Background: The initial diagnosis of systemic lupus erythematosus (SLE) is
made in a number of clinical settings, which include referrals to a specialist
because of a constellation of symptoms and/or abnormal laboratory
findings. Although a positive antinuclear antibody (ANA) test has been
regarded a serological hallmark of SLE, it is also associated with a number of
other systemic autoimmune rheumatic diseases (SARD). We studied the
serological features of patients who were referred through a central triage
(CT) system because of positive ANA and were then diagnosed as having
SLE by the consulting rheumatologist.
Methods: Patients who met four criteria were included in the SLE cohort:
referred to CT over 3 years; reason for referral was positive ANA; evaluated by
a certified rheumatologist; and diagnosed as SLE. Clinical information from
the first rheumatologic visit was extracted from the consultant’s report. An
anonymous CT database was developed to contain clinical information and
an anonymous serological database was used for autoantibody test results.
Results: A total of 15,357 patients were referred through the CT; 643 (4.1%)
because of positive ANA and, of these 263 (40.9%) were evaluated by a
rheumatologist. In 24/263 (9.1%) ANA-positive patients, the rheumatologist
provided a diagnosis of SLE, while 39 (14.8%) had a diagnosis of another
autoantibody-related rheumatic disease (AARD), 69 (26.2%) had no evidence
o fa n yd i s e a s e ,2 9( 1 1 % )h a dc o n d i t i o n st h a td i dn o tm e e tc l a s s i f i c a t i o n
criteria for an AARD and the remainder (102, 38.8%) had a variety
of rheumatologic diagnoses. The age range of the SLE patients was 25 to
73 years (mean 44.4 years), 95.8% were female, 87.5% were referred by a
family physician and the average waiting time was 137.3 days. The
serological profile of the 24 SLE patients included 29.1% anti-Sm, 25% anti-
U1RNP, 25% anti-ribosomal P, 25% anti-SS-A/Ro60, 25% anti-Ro52/TRIM21,
8.3% anti-dsDNA but none were anti-DFS70-positive.
Conclusions: This is the first study to evaluate the serological features of
patients who were diagnosed on their first visit as having SLE after they were
referred through a CT system because of positive ANA. Approximately 10% of
the ANA referral patients were diagnosed as SLE and anti-Sm was the most
common (~29%) autoantibody detected. This study provides an assessment
of patients referred for positive ANA and implies that serological parameters
might be helpful in determining the level of urgency of the referral.
A37
Sociodemographics and epidemiology of serious infections requiring
hospitalization among adults with systemic lupus erythematosus and
lupus nephritis, 2000 to 2006
Candace H Feldman
1,2, Linda T Hiraki
3, Wolfgang Winkelmayer
4,
Francisco M Marty
1, Jessica M Franklin
1, Daniel H Solomon
1, Seoyoung C Kim
1,
Karen H Costenbader
1*
1Brigham and Women’s Hospital, Boston, MA, USA;
2Harvard School of Public
Health, Boston, MA, USA;
3The Hospital for Sick Children, Toronto, ON
Canada;
4Stanford School of Medicine, Stanford, CA, USA
E-mail: kcostenbader@partners.org
Arthritis Research & Therapy 2014, 16(Suppl 1):A37
Background: Serious infections are among the leading causes of
hospitalization, morbidity, and mortality in systemic lupus erythematosus
(SLE) patients. Patients with lupus nephritis (LN) may be especially
vulnerable. We investigated the sociodemographics and epidemiology of
serious infections requiring hospitalization in a nationwide cohort of SLE
and LN patients enrolled in Medicaid, the US federal-state insurance for
low-income individuals.
Methods: We used the Medicaid Analytic eXtract (MAX) data system,
with billing claims and demographics for >24 million Medicaid enrollees
from 47 states and Washington, DC, 2000 to 2006. We identified patients
aged 18 to 65 years with prevalent SLE (≥3 visits ≥30 days apart with
ICD-9 codes of 710.0) and prevalent LN (≥ICD-9 codes for nephritis,
proteinuria and/or renal failure on or after SLE diagnosis, ≥30 days apart).
We defined serious bacterial, viral, fungal and mycobacterial infections
resulting in hospitalization using a validated administrative database
method. We stratified infection prevalence in SLE and LN by subtype,
sociodemographic factors (age, sex, race/ethnicity, region, socioeconomic
status (SES)), and by a validated SLE comorbidity index. We used Poisson
regression to calculate incidence rates (cases/person-years) of first and
overall infection, stratified by age, sex and race/ethnicity.
Table 1(abstract A37) Serious infections requiring
hospitalization in SLE and LN patients, stratified by
sociodemographic factors and the SLE comorbidity index
Prevalent SLE
cohort
(n = 43,274)
Prevalent LN
cohort
(n = 8,096)
Total number of patients with a
serious infection, n (%)
7,823 (18.1) 3,035 (37.5)
Total number of episodes of serious
infections
17,055 7,486
Age, n (%)
18 to 34 2,738 (35) 1,489 (49.1)
35 to 50 3,385 (43.3) 1,063 (35)
51 to 65 1,700 (21.7) 483 (15.9)
Sex, n (%)
Female 7,211 (92.2) 2,684 (88.4)
Male 612 (7.8) 351 (11.6)
Race/ethnicity, n (%)
White 2,613 (33.4) 674 (22.2)
African American 3,465 (44.3) 1,568 (51.7)
Hispanic 915 (11.7) 429 (14.1)
Asian 272 (3.5) 148 (4.9)
Native American 141 (1.8) 59 (5.2)
Other 417 (5.3) 157 (5.2)
Region
Northeast 1,502 (19.2) 578 (19.0)
South 3,187 (40.7) 1,198 (39.5)
Midwest 1,736 (22.2) 748 (24.7)
West 1,398 (17.9) 511 (16.8)
SES tertile
SES 1 (lowest) 2,525 (32.3) 937 (30.9)
SES 2 2,402 (30.7) 1,001 (33.0)
SES 3 (highest) 2,441 (31.2) 935 (30.8)
SLE specific risk index
a
Index 1 (lowest) 2,298 (29.4) 1,164 (38.4)
Index 2 3,478 (44.5) 864 (28.5)
Index 3 (highest) 2,047 (26.2) 1,007 (33.2)
aSLE-specific modification of the Charlson comorbidity index developed by
MM Ward and more predictive of in-hospital mortality than the Charlson
index among SLE patients.
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age was 38 (SD 12) for SLE and 34 (SD 12) for LN. In the SLE cohort, 93%
were female, 38% were Black, 37% White and 15% Hispanic; and in the LN
cohort, 89% were female, 48% were Black, 23% White, and 17% Hispanic.
We identified 17,055 episodes of serious infections requiring hospitalization
in 7,823 SLE patients (28%) and 7,486 episodes in 3,035 LN patients (38%).
Among SLE patients, the highest percentages of infections occurred in 35 to
50 year olds, in females, African Americans, in the South and in the lowest
SES group (Table 1). The incidence rates of serious infection per 100 person-
years were 15.4 for SLE and 34.5 for LN. In both cohorts, the majority (98%)
of infections were bacterial - pneumonia and bacteremia; the most common
viral infections were herpes zoster and influenza.
Conclusions: In this diverse, nationwide cohort of SLE and LN patients, we
observed a significant burden of serious infections requiring hospitalization,
most pronounced in LN patients. Further research is necessary to examine
risk factors, particularly medication use, by sociodemographic groups.
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Background: Previous estimates of prevalence and incidence of systemic
lupus erythematosus (SLE) in the United States have varied widely due to
factors such as heterogeneous source populations, limitations with case
ascertainment, and differing case definitions. The California Lupus Surveillance
Project (CLSP) is part of a national effort funded by the Centers for Disease
Control and Prevention to determine more credible estimates of incidence
and prevalence of SLE, with a special focus on Hispanics and Asians.
Methods: The CLSP is a population-based registry designed to determine
the incidence and prevalence of SLE in San Francisco County, CA, USA.
Sources of cases included hospitals, rheumatologists, nephrologists,
commercial laboratories, and state population databases. These sources
were queried for the International Classification of Diseases, Ninth Revision
(ICD-9-CM) codes of 710.0 (SLE), 695.4 (discoid lupus), 710.8 (other
specified connective tissue disease), and 710.9 (unspecified connective
tissue disease). Laboratories were queried for serologic tests including
ANA, anti-dsDNA, anti-Smith, antiphospholipid antibodies, and low
complement levels. Pathology laboratories were queried for renal and
cutaneous biopsies consistent with lupus. Over 15,000 potential SLE
patients were identified after the initial queries, and trained abstractors
performed detailed medical chart reviews on the >5,500 patients who met
the catchment criteria of residence in San Francisco County within the
years 2007 to 2009. Cases were defined as patients with documentation of
≥4/11 of the ACR Classification Criteria for SLE. Using SAS 9.3, we
calculated prevalence and incidence rates and associated 95% confidence
intervals (CIs). Denominators for all rates were obtained from the US
Census data (revised 2000 to 2009 intercensal population files) for San
Francisco County.
Results: The preliminary overall crude prevalence and incidence of SLE in
San Francisco County was 90.4/100,000 and 5.1/100,000 respectively. The
highest prevalence of disease was observed in Black women (430.6/
100,000), followed by Hispanic and Asian (163.8/100,000 and 158.9/
100,000, respectively), and White (111.3/100,000) women (Table 1).
Conclusions: T h eC L S Pu s e sm o r ec o m p l e t ec a s ef i n d i n gm e t h o d st o
provide current estimates of prevalence and incidence in a racially and
ethnically diverse population. Racial and ethnic disparities in SLE were
confirmed with the highest burden of disease in Black women, followed by
Hispanic and Asians, and, finally, White women.
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Background: We investigated incidence rates of serious infections among
children with systemic lupus erythematosus (SLE) and lupus nephritis (LN)
enrolled in Medicaid, the US health insurance program for low-income
children and parents.
Methods: We identified all children aged 5 to <18 years with SLE (≥3 ICD-9
codes of 710.0, each >30 days apart) and LN (≥2I C D - 9c o d e sf o rr e n a l
disease on/after SLE diagnosis) in the Medicaid Analytic eXtract (MAX) from
2000 to 2006. This dataset contains all outpatient and inpatient Medicaid
claims for enrollees in 47 US states and the District of Columbia. Filled
prescriptions were documented and patients were classified as new users of
Table 1(abstract A38) Preliminary prevalence and incidence rates (per 100,000) of SLE in San Francisco County, CA, USA
Prevalence (2007) Incidence (2007 to 2009)
Race/ethnicity, sex Number of cases Crude rate (95% CI) Number of cases Crude rate (95% CI)
Overall 704 90.4 (84.0 to 97.3) 121 5.1 (4.3 to 6.1)
Women 623 162.0 (149.8 to 175.2) 112 9.6 (8.0 to 11.5)
Men 81 20.6 (16.5 to 25.5) 9 0.7 (0.4 to 1.4)
Black 138 243.0 (205.7 to 287.0) 27 15.9 (10.9 to 23.1)
Women 121 430.6 (360.5 to 514.2) 25 29.9 (20.3 to 44.2)
Men 17 59.2 (37.0 to 94.9) 2 2.3 (0.6 to 8.4)
White 255 58.1 (51.4 to 65.7) 43 3.2 (2.4 to 4.3)
Women 230 111.3 (97.8 to 126.6) 38 6.0 (4.4 to 8.3)
Men 25 10.8 (7.3 to 15.9) 5 0.7 (0.3 to 1.7)
Asian 264 95.8 (84.9 to 108.1) 39 4.6 (3.4 to 6.3)
Women 233 158.9 (139.8 to 180.7) 37 8.3 (6.0 to 11.4)
Men 31 24.0 (16.9 to 34.1) 2 0.5 (0.1 to 1.9)
Hispanic 99 87.7 (72.1 to 106.8) 17 4.9 (3.1 to 7.8)
Women 87 163.8 (132.9 to 202.0) 16 9.8 (6.0 to 15.9)
Men 12 20.1 (11.5 to 35.1) 1 0.5 (0.1 to 3.1)
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Page 16 of 23hydroxychloroquine (HCQ), corticosteroids (CS) and immunosuppressants
(IS). We identified serious infections from hospital discharge diagnosis codes
for all infections, and for specific subtypes of infections (bacterial, fungal and
viral). We calculated incidence rates per 100 person-years (PY) overall and by
medication subgroup. Incidence rate ratios (IRR) (95% CI) were calculated
comparing CS, IS and CS+IS with HCQ alone using Poisson models, adjusted
for age, sex and duration of enrollment in Medicaid.
Results: Among the 2,403 children with SLE who were new medication
users, there were 316 serious infections in 2,215 PY. Incidence rates for all
serious infections requiring hospitalization varied between 10/100 PY for SLE
and 25.7/100 PY for LN. Among children with SLE receiving CS alone,
incidence rates of serious infections were 3.5 times higher compared with
those not receiving CS or IS. Among children receiving both CS and IS,
overall serious infection incidence rates were twice as high compared with
children not receiving either medication (Table 1).
Conclusions: Infection remains a common complication of SLE and is
associated with significant morbidity and mortality. We observed high rates
of serious infections requiring hospitalization among children with SLE and
LN. Those children receiving CS alone or in combination with IS had much
higher rates of serious infections, compared with those children receiving
HCQ alone.
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Background: Previous reports suggest smoking may be a risk factor for
developing systemic lupus erythematosus (SLE). This study explores the
impact of tobacco smoke on SLE patients compared with controls and on
disease characteristics among patients.
Methods: Data from a cohort of SLE patients and controls were utilized.
Medical history, smoking and secondhand smoke exposure history, SLE
Disease Activity Index (SLEDAI) and SLICC Damage Index (SDI) scores were
collected at an in-person enrollment visit and confirmed by chart review.
Statistical analysis used chi-square testing and multivariate logistic
regression.
Results: There were 545 SLE patients and 386 controls with data available
for analysis (Table 1). At enrollment, the mean age was 37.6 ± 14.7 years for
patients and 42.0 ± 15.4 years for controls. Differences between current and
never smokers (P = 0.51) and ever and never smokers (P = 0.70) were not
significantly different between patients and controls. Compared with
unrelated controls, African American patients were significantly more likely to
be exposed in the home to secondhand smoke before the age of 18 (OR
1.81, 95% CI 1.13 to 2.89). Damage by SDI (SDI > 0) was significantly
associated with ever smoking (OR 3.08, 95% CI 1.4 to 6.6), current smoking
(OR 3.17, 95% CI 1.1 to 9.1), and secondhand smoke exposure in childhood
(OR 1.91, 95% CI 1.0 to 3.6). No significant relationship was found between
smoking status and active disease at enrollment (SLEDAI ≥ 6) or dsDNA
autoantibodies. Discoid rash was significantly associated with ever smoking
(OR 2.74, 95% CI 1.5 to 5.1) and current smoking (OR 4.85, 95% CI 2.2 to 10.5).
Conclusions: Our study suggests that secondhand smoke during childhood
may be a risk factor for SLE. Secondhand smoke during childhood, current
smoking and past smoking contribute significantly to disease damage
among patients with SLE.
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Background: Lupus outcomes including mortality have been found to be
worse in most ethnic minorities, but little is known about North American
Indigenous people (NAI). We compared mortality in NAI systemic lupus
erythematosus (SLE) patients with Caucasian and other ethnic minority
(OEM) SLE patients at a single academic center.
Methods: Patients were followed from 1990 to 2013 using a custom
database. Variables included date of birth, diagnosis, year of disease onset,
ethnicity, clinic visit dates, and vital status if known. Records of all patients
with a diagnosis of SLE (≥4 American College of Rheumatology criteria)
were abstracted. For patients who had not been seen in the last 2 years,
Table 1(abstract A39)
Systemic lupus erythematosus Lupus nephritis
Unadjusted IRR (95%CI) MV-adjusted
a IRR (95% CI) Unadjusted IRR (95%CI) MV-adjusted
a IRR (95% CI)
HCQ Reference Reference Reference Reference
CS 5.25 (4.07, 6.78) 3.58 (2.79, 4.59) 2.13 (1.51, 3.01) 1.90 (1.36, 2.67)
IS 2.58 (1.86, 3.58) 2.46 (1.80, 3.37) 1.28 (0.80, 2.05) 1.12 (0.70, 1.78)
CS+IS 2.90 (2.03, 4.14) 1.99 (1.41, 2.80) NR NR
NR, not reported in accordance with CMS policy.
aMultivariable adjusted models included age, sex, race/ethnicity, US residential region, area-level SES, SLE
severity index.
Table 1(abstract A40)
Never smokers,
n (%)
Ever smokers,
n (%)
Current smokers,
n (%)
Secondhand smoke < 18 years
old, n (%)
Secondhand smoke
ever, n (%)
All patients (n = 545) 407 (74.7%) 138 (25.3%) 72 (15.1%) 132 of 372 (35.5%) 158 of 376 (42.0%)
African American patients (n
= 416)
328 (78.9%) 88 (21.2%) 49 (11.8%) 111 of 313 (35.5%) 127 of 315 (40.3%)
Caucasian patients (n = 109) 63 (57.8%) 46 (42.2 %) 21 (19.3%) 19 of 47 (40.4%) 26 of 47 (55.3%)
Other patients (n = 20) 16 (80%) 4 (20.0%) 2 (10%) 2 of 12 (16.7%) 5 of 14 (35.7%)
All controls (African American)
(n = 386)
284 (73.6%) 102 (26.4%) 57 (14.8%) 92 of 354 (25.6%) 120 of 357 (33.6%)
Related controls (n = 222) 155 (69.8%) 67 (30.2%) 36 (16.2%) 51 of 205 (24.9%) 67 of 207 (32.4%)
Unrelated controls (n = 164) 129 (78.7%) 35 (21.3%) 21 (12.8%) 41 of 149 (27.5%) 53 of 150 (35.3%)
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department. Ethnicity was by self-report, and categorized into NAI,
Caucasian and OEM. The age at diagnosis, disease duration and age at last
follow-up or age at death was calculated and compared between ethnic
groups. Survival time was compared between ethnic groups using Kaplan-
Meier and Cox proportional hazard models.
Results: A total of 807 patients with SLE were identified: 201 (25%) patients
were NAI, 501 (62%) were Caucasian, and the remaining 105 (13%) were
OEM. NAI and OEM patients were younger at diagnosis (NAI = 32 ± 15 years;
OEM = 31 ± 14 years; Caucasian = 37 ± 15 years; P = 0.001), had a shorter
disease duration (NAI = 11 ± 9 years; OEM = 10 ± 9 years; Caucasian = 15 ±
11 years; P = 0.001) and had more frequent nephritis (NAI = 41%; OEM =
49%; Caucasian = 29%; P = 0.001) compared with Caucasians. More NAI had
died by the end of the follow-up period (NAI = 25%; OEM = 7%; Caucasian =
18%; P < 0.001) and mean age at death was much younger in both NAI and
OEM (NAI = 50 ± 16 years; OEM = 46 ± 14 years; Caucasian = 63 ± 16 years;
P = 0.001). Survival rates were significantly worse in NAI compared with
OEM and Caucasians (Figure 1): 10-year survival 85% versus 97% and 92%;
15-year survival 75% versus 89% and 88% respectively (P < 0.001). In a Cox
proportional hazards model, the risk of death following diagnosis was
higher for NAI (hazard ratio 2.5; 95% CI: 1.6 to 3.9) after adjustment for onset
age, damage, and lupus manifestations.
Conclusions: NAI and OEM patients had similarly young onset age and
more frequent nephritis, but survival was markedly worse in NAI compared
with Caucasians. Urgent improvements in care delivery for NAI with SLE are
needed to decrease the significant morbidity and mortality burden from this
disease.
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Background: The Physician Global Assessment (PGA) is an important and
useful outcome measurement of lupus disease activity. Consensus on when
the PGA should be performed is lacking; many lupus specialists determine
the PGA at the time of a patient visit while others determine the PGA after
receipt of laboratory values. The objective of this study was to collect
preliminary data to determine the optimal time to perform a PGA.
Methods: In this pilot study, a PGA was performed by a single clinician
upon completion of an outpatient clinical encounter and again after
receipt of pertinent laboratory values. The pre-laboratory PGA was
determined with knowledge of the subject’s previous laboratory values
and lupus history, while the post-laboratory PGA was determined after
laboratory reports from the patient clinical encounter were also available.
Disease activity could range from 0 to 3, with 0 representing no disease
activity, 1 representing mild disease activity, 2 representing moderate
disease activity and 3 representing the most severe lupus disease
imaginable. Laboratory values obtained at each clinical visit included a
CBC, comprehensive chemistries, C3, C4, anti-dsDNA, urinalysis and, if
pertinent, a spot urinary protein/creatinine ratio. Disease duration and
SELENA SLEDAI were recorded. Results are presented using descriptive
statistics; the paired Student’s t test was utilized to compare the pre-
laboratory PGA with the post-laboratory PGA.
Results: Thirty-three patients, three male and 30 female with an average
SLE disease duration of 12.3 (range 1 to 36) years, contributed 74
assessments to this study. The average SELENA SLEDAI was 2.21. The
average pre-laboratory PGA was 0.45 and the average post-laboratory
PGA was 0.55 (P = 0.02 paired Student’s t test). Twenty-six pre-laboratory
PGAs were evaluated as 0, 23 remained at 0 after receipt of laboratory
examinations, and three increased secondary to new lupus serologic
activity. The pre-laboratory and post-laboratory PGAs were equal in 17 of
53 encounters with disease activity (that is, PGA > 0). The average pre-
laboratory PGA of these 53 encounters was 0.67, the average post-
laboratory PGA was 0.77 (P <0 . 0 5 ,p a i r e dS t u d e n t ’s t test) and the
average SELENA SLEDAI was 3.12 (range 0 to 8).
Conclusions: In some lupus patients, the PGA determined prior to receipt
of laboratory values may be the same as the PGA determined after labs are
received. However, in these preliminary data, there was a significant
difference between pre-laboratory and post-laboratory PGA. Further
studies in a larger patient population are needed to confirm and extend
these findings.
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Background: The purpose of this project is to develop a systemic lupus
erythematosus (SLE) response index as a standard outcome measure in
future therapeutic trials. Currently, there is no widely validated method for
defining response to therapy. Most SLE trials to date have failed to meet
predesigned endpoints, leading to controversy over whether it is drug
treatments or outcome measures that are unsuccessful in SLE. A similar
controversy in rheumatoid arthritis (RA) years ago was resolved by
examining data from placebo-controlled trials with drugs that were only
modestly effective. Important clinical variables were selected, criteria for
patient improvement determined, and an index was developed that
distinguished treated patients from those getting placebo. This index (ACR
20/50/70) used in RA trials has led to approval of more than 20 drug
therapies.
Methods: Now that large-scale SLE clinical trial data exist, we propose to
use the approach that was successful in RA. We will perform a post-hoc
analysis of the raw data from the BLISS-52 and BLISS-76 trials
investigating belimumab for SLE. The disease activity indices (SELENA
SLEDAI and BILAG) will be deconstructed and individual clinical and
laboratory parameters will be identified (for example, rash, complement).
The variables that are present in the majority of patients, improve over
time, and have face validity will be selected for this index. Both the
physician global assessment and a patient-related measure of quality of
life will be included.
Results: Study data will be split 50/50 into a training set and a validation
set. Baseline values of variables will be compared with values at the end of
the study to determine the degree of improvement or deterioration
occurring in individual patients during the study. We will examine various
threshold percent-improvement cutoff points across sets of variables,
selecting those that produce the largest difference between placebo-treated
and drug-treated patients while retaining an acceptably low proportion of
improved placebo-treated patients. We will follow the methodology
outlined by Harold Paulus in previous work for RA. The index will be tested
by applying it to the remaining set of study subjects (validation set) used to
derive the criterion. Performance measures will include discriminative ability,
calibration and overall accuracy.
Figure 1(abstract A41) Kaplan-Meier survival curve.
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individual patient clinical trial data, and will include patient-reported
outcome measures. The index should serve to prevent useful drugs from
being discarded due to inadequate trial designs. Preliminary data will be
presented.
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Background: There is growing recognition and concern regarding cognitive
dysfunction in patients with systemic lupus erythematosus (SLE). SLE
patients have accelerated atherosclerosis, which is known to contribute to
cognitive dysfunction in other disease states. Impaired cerebrovascular
reactivity (CVR) is a vascular measure linked to cognitive dysfunction, but
this has not been well studied in the setting of SLE. The objectives of this
study are to determine whether CVR is impaired in patients with SLE and to
determine the significance of CVR impairment.
Methods: Right middle cerebral artery CVR was assessed by the breath
holding index (BHI), which combines transcranial Doppler recording and
passive breath holding. This technique evaluates changes in middle
cerebral artery Doppler velocities upon permissive hypercapnea. We
measured the BHI in nine female patients with SLE (age 38 ± 13 years) and
12 age-matched controls. Cognitive function was assessed using the color
Stroop block time test (SBT) and the Stroop black/white test (SBWT). The
augmentation index, a measure of arterial wave reflection, was assessed by
applanation tonometry of the radial artery. Carotid intimal media thickness
measurements were obtained with high-resolution ultrasound.
Results: Completion times for the SBT (38.4 ± 8.7 vs. 29.5 ± 6.6) and the
SBWT (29.7 ± 5.4 vs. 22.9 ± 5.8) were significantly higher in SLE patients
versus controls (P = 0.005 and P = 0.004 respectively). On CVR testing,
right middle cerebral artery BHI responses were significantly different
between SLE and NLS (0.91 ± 1.10 vs. -0.99 ± 1.7, P = 0.001). There was a
trend towards higher CIMT (0.634 ± 0.130 cm vs. 0.549 ± 0.116 cm, P =
0.10) and towards higher AI (27 ± 16% vs. 18 ± 9%, P = 0.10) in the SLE
group. CVR was significantly correlated with AI (0.68, P = 0.003), and a
trend with SBT (r = 0.42, P = 0.07) and CIMT (r = 0.45, P = 0.08). On
multivariate analysis (with age and SLE), SLE was a significant predictor of
BHI (B = 1.84, P = 0.033).
Conclusions: SLE is associated with impaired CVR. Impaired CVR appears
related to higher wave reflection as measured by the AI. This ongoing study
will help define the relations between CVR and other vascular parameters as
well as potential relations with cognitive dysfunction in SLE patients.
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Background: ‘Lupus headache’ is controversial but included in measures
of global SLE disease activity. We examined the frequency, characteristics
and associations of ‘lupus headache’ in a large, prospective, inception
cohort of SLE patients.
Methods: The study was conducted by an international network of 30
academic medical centers. Annual assessments were performed for 19
neuropsychiatric (NP) syndromes, which included five types of headache
using the International Headache Society (IHS) criteria. Additional data were
demographic and clinical variables, SLEDAI-2K, which includes ‘lupus
headache’ as a standalone variable, SLICC/ACR damage index and self-report
mental (MCS) and physical (PCS) component summary scores of the SF-36.
Statistical analysis used linear regression models with generalized estimating
equations.
Results: Of 1,732 enrolled patients, 89% were female. Race/ethnicity was
Caucasian (48%), African (16%), Asian (16%), Hispanic (16%) and other (4%).
At enrollment, the mean ± SD age was 34.6 ± 13.4 years, disease duration
was 5.6 ± 4.8 months and follow up was 3.8 ± 3.1 years. Twenty-six (1.5%)
patients had ‘lupus headache’ at 27 (0.36%) of 7,523 assessments with the
following IHS classification: migraine (n = 13), tension headaches (n =8 ) ,
intractable nonspecific headaches (n =5 ) ,c l u s t e rh e a d a c h e s( n =1 )a n d
intracranial hypertension (n = 1). In 5/27 (18.5%) assessments there were
concurrent NP events. ‘Lupus headache’ was reported at both enrollment
(n = 14) and follow-up (n = 13) assessments, in patients from all racial/ethnic
groups in 15 of 30 (50%) sites located in eight of 11 countries. The
estimated mean (± SE) SLEDAI-2K scores, without the ‘lupus headache’
variable, for visits with no headache (n = 6,019), a nonlupus headache (n =
1,330) and both a nonlupus headache and ‘lupus headache’ (n =2 7 )w e r e
3.8 ± 0.08, 3.6 ± 0.18 and 7.2 ± 1.40 respectively (P = 0.034). Concurrent SF-
36 MCS scores were 47.8 ± 0.28, 42.6 ± 0.56 and 39.4 ± 2.41 (P < 0.001) and
PCS scores were 42.6 ± 0.30, 38.1 ± 0.53 and 32.4 ± 1.76 (P < 0.001). SLEDAI-
2K scores, without the ‘lupus headache’ variable, for patients with and
without ‘lupus headache’ were 7.2 ± 1.40 versus 3.7 ± 0.08 (P =0 . 0 3 5 ) .I n
5/26 (19.2%) patients, ‘lupus headache’ was the sole contributor to the
SLEDAI-2K score. Concurrent SF-36 MCS and PCS scores for patients with
and without ‘lupus headache’ were 39.4 ± 2.41 versus 46.8 ± 0.27 (P = 0.002)
and 32.4 ± 1.76 versus 41.7 ± 0.28 (P < 0.001) respectively.
Conclusion: ‘Lupus headache’ was infrequent, associated with higher global
disease activity and a lower HRQoL. It was not reproducibly aligned with a
uniform IHS classification of headache (for example, intractable headache).
The lack of consistency in diagnosing ‘lupus headache’, even by experienced
clinicians, indicates a need to better define ‘lupus headache’ and to reach
consensus on whether it is truly a standalone manifestation of NP SLE.
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Background: Patients with systemic lupus erythematosus (SLE) are at
increased risk for adverse pregnancy outcomes and cardiovascular disease
(CVD). The objective of this exploratory study was to investigate the
association between a history of adverse pregnancy outcomes and
subsequent risk of subclinical CVD assessed by imaging studies and verified
clinical CVD events in 129 women with SLE.
Methods: The occurrence of adverse pregnancy outcomes, specifically pre-
eclampsia, preterm birth, and low birth weight, was ascertained by
questionnaire. Subclinical CVD was assessed by coronary artery calcium
(CAC) as measured by electron beam computed tomography (EBCT) and
carotid plaque measured by B-mode ultrasound. Clinical CVD events were
verified by medical record review. Logistic regression was used to estimate
the association of pregnancy complications with occurrence of subclinical
and clinical CVD with ap r i o r iadjustment for age, which is associated with
CVD and SLE disease duration as a measure of SLE disease burden.
Results: Fifty-six women reported at least one pregnancy complication
while 73 had none. Twenty-six women had at least one pregnancy
complicated by pre-eclampsia and were more likely to have a CAC score
≥10 (adjusted odds ratio (OR) = 3.7; 95% confidence interval (CI): 1.2, 11.9),
but the presence of plaque was not associated with this pregnancy
complication (OR = 1.1; 95% CI: 0.4, 2.8). Low birth weight and preterm birth
were not associated with CAC or plaque.
Conclusions: SLE patients with a history of pre-eclampsia had a higher
rate of subclinical CVD as measured by CAC score. Future studies are
needed to confirm the relationship between adverse pregnancy outcomes
and subsequent subclinical CVD and clinical CVD events.
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Background: Variations in methodological quality can affect the results of
individual studies and of systematic reviews. We examined the adequacy
of patient descriptions, representativeness, and follow-up information in
studies included in a systematic review of risks of end-stage renal disease
(ESRD) in patients with lupus nephritis.
Methods: We search Medline, Embase, and the Cochrane Database from
their inceptions to 31 December 2013 for studies that reported on ESRD in
adults with lupus nephritis. We included all observational studies and long-
term clinical trials with a minimum of 12 months of follow-up and 10
patients that reported specific data on the development of ESRD. Two
authors independently assessed study quality using a modification of the
Newcastle Ottawa scale, and rated studies on 10 items in three areas:
adequacy of description of the cohort (items 1 to 3); representativeness
(items 4 to 7); and adequacy of follow-up information (items 8 to 10).
Results: The literature search yielded 1,852 articles, of which 174 articles
met our inclusion criteria. These included 132 observational studies and 42
clinical trials. The proportion of studies meeting each quality measure,
stratified by study design, is presented in Table 1. Among observational
studies, the median number of measures satisfied per study was 5 (range 2
to 9), and among clinical trials was 4 (range 2 to 7). There was no correlation
between publication year and number of measures satisfied for
observational studies (r = 0.14), but recent trials tended to satisfy more
quality measures (r =0 . 3 2 ;P = 0.04).
Conclusions: While both observational studies and clinical trials generally
provided good clinical descriptions of the cohorts, few provided adequate
data on follow-up. The representativeness of observational studies was low.
The improvement in trial quality over time may be due to the development
of standardized protocols and the institution of reporting standards, which
might also serve to enhance the reporting of observational studies.
Acknowledgements: Supported by the Intramural Research Program,
NIAMS/NIH.
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Background: The Patient-Centered Outcomes Research Institute (PCORI)
was established to support research that informs US health reform. The
PCORI aims to provide patients and the public with information to
facilitate healthcare decision-making, including to ‘develop, refine, test,
and/or evaluate patient-centered approaches, including decision support
tools.’ Here we describe the first PCORI project in systemic lupus
erythematosus (SLE), in which we aim to develop an individualized patient
decision aid for lupus nephritis. The project uses a multiphase approach to
develop and test a decision aid, combining comparativee f f e c t i v e n e s s
research, qualitative research with patients, decision-aid prototype
development, and a randomized controlled trial.
Methods: We performed comparative effectiveness research (CER) using
state-of-the-art network meta-analyses to assess effectiveness and
toxicities of treatments for lupus nephritis. Concurrently, patients with
lupus nephritis participated in Nominal Group Technique (NGT) groups.
Participants identified facilitators and barriers they faced when considering
and taking drugs for lupus nephritis. In the coming year, information from
the CER and NGT will be used to create a prototype decision aid, with
input from diverse project stakeholders, including design consultants,
clinicians, researchers, lupus organizations and patients. We will then
perform a randomized controlled trial to assess the effectiveness of the
decision aid (vs. usual care) in patients with incident or recurrent lupus
nephritis. Primary outcomes include measures of decisional conflict and
informed choice. Secondary outcomes include the control preferences
scale and interpersonal processes of care, and exploratory outcomes will
include medication adherence and persistence, cumulative glucocorticoid
exposure, and renal response.
Results: The CER and NGT have been completed. Fifty-two patients, who were
predominantly African American and Hispanic, participated in NGT groups.
Patients identified barriers and facilitators to use of immunosuppressive drugs
in two 1-hour sessions, each with three to nine patients. Data from CER and
NGT are currently being analyzed. A prototype decision aid will be developed
based on the results of the CER and NGT, and subsequently piloted in patients
before the randomized trial.
Conclusions: The decision aid resulting from this project will be
nonproprietary, free of cost and readily available for use both in the United
States and internationally. Use of the tool is expected to facilitate patient-
centered care for lupus nephritis by providing information that both
scientific evidence and patients themselves indicate is critical before
commencing therapy. The project aims to improve decision-making and
health outcomes for lupus nephritis, particularly among racial/ethnic
minorities.
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Table 1(abstract A47)
Quality measure Observational studies (n = 132) Clinical trials (n = 42)
1. ACR criteria for SLE used 88.3 88.1
2. Measure of renal function included 77.2 95.2
3. Treatments described 84.1 100
4. Community-based study 11.3 Not applicable
5. Inception cohort 40.1 11.9
6. Renal biopsy not required for inclusion 37.1 35.7
7. Patients with chronic kidney disease not excluded 80.3 23.8
8. Losses to follow-up described 24.2 42.8
9. Losses to follow-up < 20% 18.9 30.9
10. Data reported using Kaplan-Meier curves 36.3 9.5
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Background: Belimumab is a human monoclonal antibody that inhibits
soluble B-lymphocyte stimulator and improves systemic lupus
erythematosus (SLE) disease activity. This study was initiated to evaluate the
use and efficacy of belimumab in academic SLE clinical practices.
Methods: An invitation to participate was sent to 16 physicians experienced
in SLE phase III clinical trials. All agreeing to participate completed a one-
page questionnaire for each patient prescribed belimumab that includes
demographic and SLE characteristics, and information about belimumab
administration. The questionnaire completed every 3 months by the
physicians also captured clinical responses and belimumab safety. Clinical
response was defined as a ≥50% improvement in the initial clinical
manifestation being treated without worsening in other organ systems.
Results: Of 16 invitations sent, nine investigators participated. Questionnaires
on 150 patients treated with belimumab for at least 3 months were available
for analysis. The mean age was 41.9 ± 12.6 years. 92.0% were female, 67.1%
White, 24.7% Black, 5.7% Asian, and 5.3% Hispanic. The average SLE disease
duration was 12.2 ± 8.2 years. Concomitant medications included: prednisone
in 73.3% (mean dose of 12.2 ± 10.9, 41.7% on ≥10 mg), antimalarials in
71.7%, and immunosuppressants in 66.3% (mycophenolate mofetil 34.2%,
azathioprine 20.3%, methotrexate 11.8%). Only 3.7% of patients were not on
any background SLE medications, 8.0% were on antimalarials alone. The
dominant clinical manifestations driving treatment were arthritis in 69.5%,
rash in 44.4%, and inability to taper steroids in 27.3%. Other SLE
manifestations were serositis 16.0%, hematological 13.9%, and renal 10.7%. A
total 65.2% of patients had ≥2 active manifestations. Of the 150 patients on
belimumab for at least 3 months, 69 (46.0%) clinically responded by 3
months with marked improvement in arthritis and/or rash. Similarly, of the
112 patients on belimumab for at least 6 months for whom follow-up data
were available, 54 (48.2%) clinically responded with improvements in arthritis,
rash and/or nephritis. While the numbers are limited, black patients showed
improvement at 6 months, with 19/26 (73%) of patients responding, P =0 . 0 5 .
Conclusions: These observational data support the use of belimumab
across all racial/ethnic groups and ef f i c a c ys i m i l a rt ot h a tr e p o r t e di nt h e
phase III trials. Relevant to physician and patient decision-making,
improvement was seen as early as 3 months.
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Background: Antiphospholipid syndrome (APS) is defined as the
occurrence of venous or arterial thrombosis and/or pregnancy morbidity,
in the presence of serological evidence of antiphospholipid antibodies
(including IgM and IgG anticardiolipin antibodies, IgM and IgG anti-b2-
glyoprotein I antibodies, or the lupus anticoagulant). Whereas most
patients with focal thrombotic events respond to anticoagulation,
occasional patients are refractory to standard therapeutic interventions
and continue to have either focal or multifocal occlusive disease. For those
with recalcitrant disease or those with the catastrophic antiphospholipid
syndrome (CAPS), physicians resort to the addition of antiplatelet agents,
steroids, immunosuppressives, IVIG, rituximab, or plasma exchange.
Complement inhibition may be an effective way to prevent thrombosis
associated with APS. Eculizumab, a monoclonal antibody that binds to
complement protein C5 and prevents the conversion of C5 to C5a and C5b,
may potentially be an effective treatment for patients with APS. First studied
in patients with systemic lupus erythematosus, rheumatoid arthritis,
dermatomyositis, and idiopathic membranous nephropathy in the early
2000s, development of the drug for rheumatic diseases was abandoned in
favor of paroxysmal nocturnal hemoglobinuria and atypical hemolytic
uremic syndrome. Given the experience of complement inhibition in animal
models of APS as well as prior use of eculizumab several years ago in one of
our refractory APS patients, we administered eculizumab to two patients
with severe refractory APS.
Methods: Two patients with antiphospholipid syndrome, unresponsive to
conventional anticoagulant therapy, were treated with a loading dose of
eculizumab followed by dosing every other week (atypical hemolytic uremic
syndrome dosing schedule). It has been suggested that the platelet count
may be used as a surrogate marker of APS activity. During therapy, both
patients’ platelet counts were monitored and any new thrombotic events
documented. At the time of submission of this abstract, both patients are
continuing treatment with eculizumab.
Results: At their lowest values, the patients had platelet counts of 35,000
and 22,000 (K/ml). One of the patients was steroid dependent in order to
maintain her platelet count. After initiation of eculizumab, the patient was
able to taper steroids as the platelet count has risen from a low of 35,000 to
average counts of 100,000. The second patient’s platelet count rose to over
200,000 from 22,000 within 10 days of receipt of eculizumab. For both
patients the increases in platelet counts have been sustained other than
during brief periods when therapy was delayed. During the treatment period
(4 and 8 months), there were no new thrombotic events. See Figure 1.
Conclusions: Eculizumab has shown promising results in our patients with
refractory antiphospholipid syndrome. Longer follow-up of these patients
will be needed in order to discern the effect on thrombosis. Controlled
studies are needed to further assess the efficacy of eculizumab in this
condition, as are mechanistic studies.
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Background: Development of new systemic lupus erythematosus (SLE)
treatments has been slow. To accelerate the pace, an evidence-based
approach was developed to find new lupus therapies amongst 6,800
compounds FDA approved for human use.
Methods: The Lupus Treatment List (LRxL) was constructed with intense
input from the entire lupus community, including patients, and was used to
prioritize therapies to be tested in small focused, biomarker-rich clinical trials
(SLE Treatment Acceleration Trials (STAT)). All drugs widely used for lupus or
known to be in development for lupus by Pharma/Biotech were excluded.
Details of the project can be viewed online [1]. A novel evidence-based
composite scoring system was developed to rank the identified drugs/
therapies numerically by scientific rationale, experience in lupus mice/
human cells, previous clinical experience in autoimmunity, drug properties
and adverse event profile.
Results: Of the 157 therapies initially screened, more than 25 have an
appropriate set of characteristics to consider for testing in clinical trials in
lupus, including drugs targeting cellular metabolism, kinases, the immune
Figure 1(abstract A50) APS patients treated with eculizumab:
platelet counts.
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Page 21 of 23system, HDACs, complement as well as cellular therapies and nondrug
interventions.
Conclusions: This approach has not only identified unique candidates
that could be useful in SLE and possibly other autoimmune/inflammatory
conditions, but has also yielded a rigorous evidence-based process by
which therapies can be usefully rated for possible clinical application to
treat these conditions, thereby mitigating risk in drug development.
Reference
1. LrXL STAT. [http://www.linkedin.com/in/lrxlstat].
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Background: Treatments for systemic lupus erythematosus (SLE) include
corticosteroids (CS), antimalarials, nonsteroidal anti-inflammatory drugs,
cytotoxic agents, and immunosuppressive/immunomodulatory agents. We
examined treatment patterns in newly diagnosed SLE patients from a
multipayer US claims database.
Methods: This study (GSK HO-13-13054) retrospectively followed incident
SLE patients’ treatment for 4 years in the MarketScan commercial claims
database. The earliest medical claim date with SLE diagnosis (ICD-9 code
710.0x; 1 January 2002 to 31 March 2008) was the index date. Patients were
≥18 years at index, had continuous medical and pharmacy benefits for
12 months pre index without SLE diagnosis and 48 months post index, with
≥1 SLE-related inpatient claim or ≥2 office or emergency room visits with
SLE diagnosis ≥30 days apart within 12 months post index. A specialist must
have made ≥1 SLE diagnosis at index or within 12 months post index.
Results were stratified by provider type (primary care physician (PCP)/
specialist). A disjoint k-means cluster analysis identified treatment pathways
using annual prescription numbers for CS, hydroxychloroquine (HCQ),
mycophenolate mofetil, azathioprine, and methotrexate as input variables.
Results: The study identified 2,086 newly diagnosed SLE patients (mean
age: 47.2 years; female: 91%). In the 4 years post index, 1,031 (49.4%)
patients were not actively treated (<0.05 prescriptions/year). Of the 219
(10.5%) patients who primarily received CS, 42 had persistently high
numbers of prescriptions (~1/month), and 177 received 4.9 (mean)
prescriptions in Year 1, decreasing in Years 2 to 4. Three subgroups
emerged within the 606 (29.1%) patients who primarily received HCQ:
persistent high number of prescriptions (~1/month), persistent moderate
number of prescriptions (3.2 to 4.1/year), and poor adherence (Year 1, 8.7
prescriptions; Years 2 to 4, decreasing prescriptions). Both CS and HCQ were
received by 138 (6.6%) patients; 56 had high numbers of prescriptions (Years
1 to 4); 82 showed progressively decreasing prescriptions. Fifty-four (2.6%)
and 38 (1.8%) patients had moderate numbers of prescriptions for
methotrexate (5.4 to 8.4/year) and azathioprine (5.7 to 7.5/year), respectively,
with some CS and HCQ prescriptions. Treatment patterns differed in patients
seen by specialists versus PCPs (P < 0.0001). Specialist-treated patients had a
lower no-treatment rate than PCP-treated patients, and higher rates in
active treatment clusters (Table 1).
Conclusions: Treatment patterns were observed among SLE patients using
medical resources. In the 4 years post diagnosis: ~50% of patients were not
actively treated; 50% received CS, HCQ, and immunosuppressants with
differing combinations, intensities, and adherence levels. Specialists
provided more intensive treatment than PCPs.
Competing interests: CM, HK, JP, and SN are employees of and hold
stock in GlaxoSmithKline. DJW is a consultant for GlaxoSmithKline.
Acknowledgements: Study and editorial support (Natasha Thomas,
Fishawack Indicia Ltd) funded by GlaxoSmithKline.
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Background: Atacicept is a fusion protein that inhibits B-cell stimulating
factors BLyS and APRIL, which are elevated in systemic lupus erythematosus
(SLE). Atacicept 150 mg (A150) was associated with reduced BILAG A and B
flares in the APRIL-SLE study. We examined efficacy of atacicept in
preventing flares of SLE disease activity by the BILAG organ system and
modified SELENA SLEDAI flare index and assessed corticosteroid use during
a previously reported trial of atacicept versus placebo (PLC).
Methods: Subjects with active SLE were treated with corticosteroid taper
for 12 weeks. Subjects reaching BILAG C or D at weeks 10 and 12 were
randomized at baseline 1:1:1 to receive PLC, atacicept 75 mg (A75) or A150
twice weekly every 4 weeks then weekly for 48 weeks. All patients received
standard of care. Analysis was performed in the modified intention-to-treat
population. BILAG and SELENA SLEDAI flares and corticosteroid usage were
assessed 4 weekly.
Table 1(abstract A52) Longitudinal treatment patterns according to primary treatment by specialist or PCP
Cluster Interpretation Treated primarily by
specialists
a
Treated primarily
by PCPs
a
n % n %
1 Not actively treated throughout (<0.05 (mean) annual prescriptions) 216 26.2 815 64.6
2 CS only: high number of prescriptions (chronic use) 29 3.5 13 1.0
3 CS only: moderate number of prescriptions with slow reduction 85 10.3 92 7.3
4 HCQ only: high number of prescriptions (chronic use) 102 12.4 56 4.4
5 HCQ only: moderate number of prescriptions (chronic use) 136 16.5 134 10.6
6 HCQ only: poor adherence 111 13.5 67 5.3
7 CS plus HCQ: high number of prescriptions (chronic use) 32 3.9 24 1.9
8 CS plus HCQ: poor adherence 51 6.2 31 2.5
9 Methotrexate: moderate number of prescriptions plus some prescriptions for CS and HCQ 34 4.1 20 1.6
10 Azathioprine: moderate number of prescriptions plus some prescriptions for CS and HCQ 28 3.4 10 0.8
Total 824 100.0 1262 100.0
aPatients who visited a specialist (including a rheumatologist, dermatologist, nephrologist, ophthalmologist, or oncologist) in >50% of SLE-related office visits
were defined as primarily seen by specialists. Patients who visited PCPs in >50% of SLE-related office visits were defined as primarily seen by PCPs. The
difference in treatment patterns between the two groups was statistically significant (P < 0.0001).
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Page 22 of 23Results: The A150 arm was terminated early due to two fatal pulmonary
infections. A lower proportion of subjects with >1 BILAG system A or B
flare was observed in A150 and A75 versus PLC. Proportions of subjects
with BILAG flare in each organ system were reduced in A150 versus PLC,
except for vasculitis, which had similar proportions between groups.
BILAG flares were most commonly observed in mucocutaneous and
musculoskeletal systems. Proportions of subjects with severe SELENA
SLEDAI flare during treatment in a post-hoc analysis were 19%, 11%, and
13% for PLC, A75, and A150, respectively. There was a dose-proportional
decrease in the number of subjects who had at least one increase in
steroid dose, and an increase of ≥20 mg/day (Table 1). Atacicept induced
substantial reductions in Ig levels, which lessened during follow-up but
did not fully return to baseline over 24 weeks. Atacicept treatment effect
was observed in subjects with BLyS or APRIL levels ≥ median, but not <
median. The difference was most pron o u n c e di np a t i e n t sw i t hb a s e l i n e
BLyS and APRIL ≥ median. Atacicept-treated patients with greatest
absolute decrease in IgG and IgM experienced fewest new flares.
Conclusions: Reduction of the individual BILAG system and severe
SELENA SLEDAI flares and corticosteroid use was associated with A150
treatment. Analysis of potential predictive biomarkers identified a
subgroup of patients with higher BLyS and APRIL levels at baseline more
likely to benefit from treatment. Further studies are required to clarify
safety and efficacy of atacicept in SLE patients and associations between
biomarkers and clinical response to atacicept.
Trial registration: EudraCT: 2007-003698-13, NCT00624338
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Table 1(abstract A53) Corticosteroid exposure post-randomization, modified intention-to-treat population
Placebo Atacicept 75 mg Atacicept 150 mg
(n = 154) (n = 157) (n = 144)
Zero dose increases, n (%) 108 (70.1) 115 (73.2) 122 (85.3)
(n = 154) (n = 157) (n = 143)
Corticosteroids ≥20 mg/day, n (%) 43 (27.9) 39 (24.8) 17 (11.9)
Odds ratio 0.860 0.346
P value 0.563 0.001
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